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SUMMARY 
 
Cerebrovascular disease and coronary heart disease (CHD) are of the most important 
causes of morbidity and mortality amongst South Africans.  The risk factor prevalence for 
stroke and CHD becomes altered by changes in lifestyle, including diet.  In general it is 
suggested that lifestyle management should be the first choice when having to treat 
patients with increased cardiovascular risk. 
 
The prudent low-fat, high-fibre diet is regarded as an apparently healthy diet.  It is 
suspected that this diet is effective for the control of known coronary risk factors as well 
as raised clotting factors.  Research studies have shown the addition of dietary fibre to 
the diet as a promising therapeutic agent for the limited control of known coronary risk 
factors.  The physiological effects of dietary fibre in humans are significantly influenced by 
the degree to which fibre is fermented in the colon.  Fermentation results in the production 
of short-chain fatty acids (SCFAs); acetate, propionate and butyrate. 
 
The aim of this study was to examine the possible effects of different combinations of 
short-chain fatty acids on some metabolic risk markers. In this study a group of 
westernised African male volunteers was recruited and randomly assigned to three 
groups.  Group one received a placebo.  Group two received a supplement containing 
50% acetate and 50% propionate.  Group three received a SCFA supplement in the ratio 
of 70% acetate, 15% propionate and 15% butyrate.  Supplementation was sustained for a 
period of six weeks.  Blood samples were drawn during the different visits. 
 
 xii 
At baseline the study group represented a group of black African men without any 
apparent metabolic or physical abnormalities.  All measured variables fell within the 
normal range.  In the placebo group, there was a statistically significant decrease in 
plasma fibrinogen levels from baseline to the end of supplementation.  In the acetate-
propionate supplement study group a statistically significant decrease in factor VIII (from 
91.1 ± 11.2 to 90.9 ± 8.3%, respectively), and ATIII (from 114.3 ± 13.1 to 108.34 ± 9.5%), 
as well as a statistically significant decrease in low-density lipoprotein cholesterol (LDL-C) 
from 3.10 ± 0.79 to 2.64 ± 0.73 mmol/L.  The significant increase in %HDL-C from 26.3 ± 
6.5 to 30.2 ± 9.3% should also be noted.  Both triglycerides (8%) and plasma fibrinogen 
(2%) showed a statistically significant increase.  However, these changes are of no 
clinical significance. 
 
For the high-acetate supplement study group (with the addition of butyrate), a statistically 
significant decrease in factor VII (from 102.5 ± 13.7 to 101.1 ± 6.4%), VIII (from 92.6 ± 
12.8 to 87.6 ± 6.0%), ATIII (from 109.2 ± 16.0 to 103.0 ± 9.9%) as well as fibrin monomer 
concentration (from 13.9 ± 2.2 to 12.1 ± 3.6 mg/L), were measured.  Fibrin network 
compaction increased significantly from 14.2 ± 4.6 to 13.7 ± 4.0%.  Other changes include 
a statistically significant increase in the serum-TC of 4.2%. 
 
From the results it is evident that the acetate-propionate supplement, with exclusion of 
butyrate, has a beneficial effect on metabolic parameters when compared to a high-
acetate-propionate supplement.  The results do provide evidence of a possible 
therapeutic application for the propionate-acetate containing supplement.  The specific 
mechanism should, however, still be investigated. 
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It can be concluded from this study that acetate, propionate and butyrate each have 
different effects on human metabolism.  It is evident that the use of a mixture of acetate 
and propionate may have a beneficial effect on patients at risk of developing CVD.  
Further studies that investigate the optimum ratio of these two products may lead to the 
development of a naturally derived therapeutic product for the prevention or treatment of 
CVD in black African men, as well as the population at large. 
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OPSOMMING 
 
Serebrovaskulêre siekte en koronêre hartsiekte is van die belangrikste oorsake van 
morbiteit en mortaliteit by Suid-Afrikaners.  Die prevalensie van risikofaktore vir beroerte 
en koronêre hartsiektes word deur veranderinge in lewensstyl, insluitende dieët bepaal.  
Oor die algemeen word dit aanbeveel dat die manipulasie van lewenstyl die eerste keuse 
vir behandeling van pasiënte met verhoogde kardiovaskulêre risiko moet wees. 
 
‘n Dieët met lae vet- en hoë veselinhoud word as ‘n gesonde dieët beskou.  Daar word 
vermoed dat hierdie dieët effektief is vir die kontrolering van bekende koronêre 
risikofaktore sowel as verhoogde stollingsfaktore.  Navorsingstudies het getoon dat die 
byvoeging van dieëtvesel by die dieët ‘n belowende terapeutiese agens is vir die beperkte 
kontrolering van bekende koronêre risikofaktore.  Die fisiologiese effekte van veselinname 
in mense word beïnvloed deur die mate wat vesel in die kolon gefermenteer word.  
Fermentasie lei tot die produksie van kortkettingvetsure; asetaat, propionaat en butiraat. 
 
Die doel van die studie was om die moontlike effek van verskillende kombinasies van 
kortkettingvetsure op metaboliese risikomerkers te toets. In hierdie studie is ‘n groep 
vrywillige verwesterde swart mans gevra om deel te neem en ingedeel in drie groepe 
deur randomisering. Groep een het ‘n plasebo ontvang.  Groep twee het ‘n aanvulling 
ontvang wat 50% asetaat en 50% propionaat bevat.  Groep drie het ‘n 
kortkettingvetsuuraanvulling ontvang in die verhouding van 70% asetaat, 15% propionaat 
en 15% butiraat.  Aanvullings is vir ‘n periode van ses weke toegedien.  Bloedmonsters is 
tydens die verskillende besoeke versamel. 
 xv 
Die studiegroep het aanvanklik uit 'n groep swart mans sonder enige metaboliese of 
fisiese abnormaliteite bestaan.  Alle gemete veranderlikes het binne die normale waardes 
geval.  In die plasebogroep was daar ‘n statistiese betekenisvolle verlaging in plasma-
fibrinogeenvlakke vanaf basislyn tot met die einde van die aanvullings.  Die asetaat-
propionaataanvullingstudiegroep, het 'n statistiese betekenisvolle verlaging in faktor VIII 
(van 91.1 ± 11.2 tot 90.9 ± 8.3%, respektiewelik) en ATIII (van 114.3 ± 13.1 tot 108 ± 
9.5%) getoon, sowel as ‘n statistiese betekenisvolle verlaging in LDL-C van 3.10 ± 0.79 
tot 2.64 ± 0.73 mmol/L.  Die betekenisvolle verhoging van %HDL-C van 26.3 ± 6.5 to 30.2 
± 9.3% moet ook in aanmerking geneem word.  Beide trigliseriede (8%) en plasma-
fibrinogeen (2%) het ‘n statistiese betekenisvolle verhoging getoon. Hierdie veranderinge 
is egter van geen kliniese waarde nie.  
 
Die hoë-asetaatstudiegroep (met die byvoeging van butiraat), het ‘n statistiese 
betekenisvolle verlaging in faktor VII (van 102.5 ± 13.7 tot 101.1 ± 6.4%), VIII (van 92.6 ± 
12.8 tot 87.6 ± 6.0%), ATIII (van 109.2 ± 16.0 tot 103.0 ± 9%) getoon, sowel as 
fibrienmonomeerkonsentrasie (van 13.9 ± 2.2 tot 12.1 ± 3.6mg/L).  
Fibriennetwerkkompaksie het betekenisvol verhoog vanaf 14.2 ± 4.6 tot 13.7 ± 4.0%.   
Ander veranderinge sluit in ‘n statistiese betekenisvolle verhoging in totale serum-
cholesterol van 4.2%. 
 
Volgens die resultate is dit beduidend dat die asetaat-propionaataanvulling, met uitsluiting 
van butiraat, ‘n voordelige effek op metaboliese parameters het wanneer dit vergelyk 
word met ‘n hoë-asetaat-propionaataanvulling.  Die resultate voorsien bewyse van ‘n 
moontlike terapeutiese effek deur die propionaat-asetaat bevattende aanvulling.  Die 
spesifieke meganisme moet nog ondersoek word.  
 xvi 
 
Die studie toon dus dat asetaat, propionaat en butiraat elk verskillende effekte op 
menslike metabolisme het. Daar is bewys dat die gebruik van ‘n mengsel van asetaat en 
propionaat ‘n voordelige effek het op pasiënte met 'n risiko het om serebrovaskulêre 
siekte te ontwikkel.  Verdere studies wat die optimale verhouding van hierdie twee 
produkte ondersoek, kan lei tot die ontwikkeling van ‘n natuurlike terapeutiese produk vir 
die behandeling van serebrovaskulêre siekte in swart mans, sowel as die bevolking as 
geheel. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 BACKGROUND 
 
Cerebrovascular disease and coronary heart disease (CHD) are of the 
most important causes of morbidity and mortality amongst South Africans 
and also in the Western world (Bradshaw et al., 1995).  Furthermore, the 
incidence of the western diseases; atherosclerosis, CHD and 
cerebrovascular disease is progressively rising in black populations in 
South Africa (Mollentze et al., 1995; Kahn & Tollman, 1999).  Stroke is the 
most rampant clinical entity of cerebrovascular disease (CVD) (Steyn et 
al., 1992) and is an important cause of death in westernised black 
populations in South Africa (Joubert, 1991; Qizilbash, 1995; Kahn & 
Tollman, 1999) as well as black population in the United States of America 
(Iso et al., 1989).  The risk factor prevalence for stroke and CHD becomes 
altered by changes in lifestyle and diet.  Westernisation and migration to 
an urban environment causes an even further rise in the risk of stroke and 
CHD (Steyn et al., 1991; Seedat et al., 1992; Bourne et al., 1993; 
Mollentze et al., 1995; Solomons & Gross, 1995).  Mollentze et al. (1995) 
indicated that the black population in the Free State is already in advanced 
stages of urbanisation and westernisation, while Bourne et al. (1993) 
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found that urbanisation of black populations in the Cape Peninsula 
represents a phase towards a progressively atherogenic western diet.  
Furthermore, Slabber et al. (1997) also indicated that urban African men in 
the Free State show a tendency towards an atherogenic westernised diet, 
characterised by low-fibre, high-fat intake. 
Westernised African populations tend to have elevated fibrinogen 
concentrations (Venter et al., 1992; Slabber et al., 1997).  Venter et al. 
(1992) also demonstrated that westernisation of Africans tends to raise 
fibrinogen concentrations even before an increase in serum lipoproteins is 
observed. Raised plasma fibrinogen concentration is accepted as an 
independent risk factor for stroke and CHD (Cook & Ubben, 1990; Wolf, 
1994).  Apart from the known coronary risk factors and raised plasma 
fibrinogen levels, other haemostatic risk factors, including modified fibrin 
network structures, factor VII, factor VIII and C-reactive protein (CRP), are 
also accepted as important for the development of these westernised 
diseases (Kannel et al., 1987; Yarnell et al., 1991; Blombäck et al., 1992, 
Heinrich et al., 1994, Pan et al., 1997 Mills et al., 2002). 
The prudent low-fat, high-fibre diet is regarded as one of the controllable 
risk factors in the prevention of degenerative western diseases and is, 
therefore also effective for the control of known coronary risk factors 
(hyperinsulinaemia, hyperlipidaemia, hypertension, and obesity) as well as 
raised clotting factors (Vorster et al., 1988; Hubbard et al., 1994; Vorster et 
al., 1997).  There is some evidence that fat intake may influence factor VII 
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(Meade et al., 1986), and that fibrinogen levels may be lowered by fish oil 
(Oosthuizen et al., 1994), alcohol (Meade & North, 1977) and soluble 
dietary fibre (Silvis et al., 1990; Vorster et al., 1997a).  Veldman et al. 
(1999) also indicated beneficial effects on haemostasis through pectin 
supplementation.  Furthermore, Venter et al. (1997) stated that a 
supplement of soluble fibre might improve not only glucose tolerance and 
reduce serum lipid and lipoprotein concentrations, but also reduce 
fibrinogen concentrations.  The effect of diet on haemostatic risk factor is 
however, still controversial and not well established.  This underlines the 
importance to investigate possible effects of diet in haemostasis. 
The physiological effects of dietary fibre in humans are significantly 
influenced by the degree to which fibre is fermented in the colon 
(Cummings, 1982; Bourquin, et al., 1992).  Colonic fibre fermentation 
results in the production of short-chain fatty acids (SCFAs) acetate, 
propionate and butyrate (Bugaut & Bentejac, 1993; Muir et al., 1995). Total 
short-chain fatty acid (SCFA) production from fermentation has been found 
to be the greatest for the soluble fibre, oat bran (Bourquin et al., 1992a).  
Further effects of SCFAs on lipid metabolism (Topping & Wong, 1994), 
haemostasis (Veldman et al., 1999) and Factor VII activity (Marckmann & 
Jespersen, 1996) are also evident. 
Few results, however, are found, regarding the effect of SCFAs on 
haemostatic factors in human subjects.  Veldman et al. (1999) indicated 
that acetate has a small non-significant decrease on fibrinogen 
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concentration, but found a significant difference in the characteristics of 
fibrin networks.  The decrease in network fibrin content indicates that less 
fibrinogen is converted to fibrin, which is eventually incorporated into the 
fibrin networks, which are believed to be less atherogenic (Veldman et al., 
1999).  From these limited observation it is evident that there is a possible 
association between dietary fibre of SCFAs, fibrin network architecture and 
some other haemostatic risk factors.  This observation, however, lacks 
thorough investigation. 
 
 
1.2 HYPOTHESIS 
 
Hypothesis I 
H0 - The increase in colonic propionate by means of supplementation will 
not significantly improve the haemostatic and lipid profiles. 
H1 - The increase in the colonic propionate by means of SCFA salt 
supplements will improve the haemostatic and lipid profiles. 
 
Hypothesis II 
H0 - Doubling SCFA in the large intestine by supplementation of SCFA at 
an amount (molar) equivalent to SCFA generated by fermentation of 15 
grams mixed fibres (with an increased acetate concentration) will not 
significantly improve indicators of the haemostatic and lipid profiles. 
 5 
H1 - SCFA supplements in the large intestine will result in a significant 
improvement of haemostatic and lipid profiles; with significantly weaker 
and more permeable fibrin networks, coupled with improved lipid profiles.  
These metabolic changes would indicate a lower risk for cardiovascular 
disease. 
 
1.3 OBJECTIVE 
 
The objective of the study was to test the effects of different short-chain 
fatty acids ratio on some haemostatic and lipid risk markers for 
cardiovascular disease in westernised black men. 
 
1.4 DISSERTATION STRUCTURE 
 
The first chapter contain the introduction with the aim and motivation for 
the study.  Chapter two deals with the link between the different variables 
examined in this study and contains information needed for the 
understanding and interpretation of the study.  The materials and methods 
used during the study are presented in chapter three, while the findings 
are given in chapter four.  Chapter five discusses the results, and six 
presents the meaning of the findings and recommendations, while seven 
contains the references used in this dissertation. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
There are two separate but interrelated aspects involved in this study.  
These factors include risk markers for coronary heart disease and stroke, 
and lifestyle (diet, exercise, stress, etc.).  Coronary heart disease and 
stroke are considered as degenerative western diseases which in most 
cases can be prevented by a change in lifestyle, for example diet, physical 
activity and psychological well being.  Coronary heart disease and stroke 
in turn involves haemostatic and lipid risk markers.  Africans have the 
lowest incidence of these westernised disorders, in comparison to other 
South African population groups.  This is thought to be due to the prudent, 
low-fat high fiber diet which Africans consume.  However with increased 
urbanization and adoption of a western, high-fat low-fiber diet, it seems set 
that this will cause an increase in the incidence of the westernized 
diseases among the African population.  The protection seems to center 
around the intake of dietary fiber, which is fermented in the large intestine 
to short-chain fatty acids.  Another factor that seems set to increase the 
incidence of CHD and stroke is the lipodystrophy associated with human 
immunodeficiency virus (HIV) antiretroviral treatment.  This chapter will be 
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used to elaborate the link amongst the production of short-chain fatty acids 
and the development of lifestyle associated diseases and lay the 
foundation for the understanding of the results and the rest of this 
dissertation. 
 
2.2 DEFINITION OF TERMS  
 
2.2.1 Coronary Heart Disease 
Coronary heart disease (CHD) is in most instances due to obstruction of 
coronary vessels by atherosclerosis or thrombosis, singly or in 
combination (Ulbright & Southgate, 1991) that may result in myocardial 
infarction, sudden death, and angina pectoris.  Atherogenesis and arterial 
thrombus are closely linked and each contributes to the other, as indicated 
by both autopsy and coronary arteriography studies.  There is a dynamic 
interaction between spasm, thrombus and atherosclerotic plaque 
preceding acute coronary occlusion (Packham & Kinlough-Rathbone, 
1994). 
 
2.2.2 Stroke 
Stroke refers to the rapidly developing signs of focal and at times global 
loss of cerebral function with symptoms lasting more than 24 hours or 
leading to death with no apparent cause other than that of vascular origin 
(adapted from Hatano, 1976).  Atherothromboembolism is by far the most 
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common cause of ischaemic stroke, with haematological disorders, 
trauma, and a variety of miscellaneous disorders the cause of the 
remainder (Lindley & Warlow, 1994). 
 
2.2.3 Atherosclerosis 
Atherogenesis is the formation and development of atherosclerotic lesions 
on the surface of arteries; it generally involves a sequence of reactions 
that may take several years to become clinically overt (Ross, 1986).  It 
begins in early life but the complications of coronary heart disease do not 
usually occur until middle age (Stehbens, 1990).  The term arteriosclerosis 
actually encompasses any condition of arterial vessels that results in a 
thickening and /or hardening of the walls (Price & Wilson, 2003). 
 
2.2.4 Dietary fibre 
Dietary fibre is defined as complex polysaccharide polymers that derive 
from plant cell walls which are resistant to the action of our digestive 
secretions (Kritchevsky, 1994).  Dietary fibre is a generic term covering a 
number of substances of unique chemical composition and varying 
physiological effects.  In the colon, fibre is broken down, by fermentation, 
to methane, hydrogen, carbon dioxide, and the respective short-chain fatty 
acids (SCFAs), principally acetic, propionic, and butyric acid.  SCFAs are 
also known as volatile fatty acids.  These acids are readily absorbed by 
the intestinal mucosa and metabolised by body tissue (Kritchevsky, 1994). 
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2.2.5 Risk factor versus risk marker 
Risk factor represents those variables which are considered to contribute 
to the chances of developing CHD, for example diet and diabetes mellitus. 
While, risk marker represents those variables which are measured in the 
patient's blood that are associated with increased risk for developing CHD 
and stroke, for example fibrinogen and cholesterol. 
 
2.3 EPIDEMIOLOGY 
 
Cerebrovascular disease and coronary heart disease are important causes 
of morbidity and mortality in the western world (Renaud & Lorgeril, 1992) 
and amongst South Africans (Bradshaw et al., 1995).  Cardiovascular 
disease is the prime cause of death among the South African white, 
coloured and Indian populations, and the third most common cause of 
death among black South Africans aged 15 - 64 years (Bradshaw et al., 
1992).  Although blacks still have the lowest cardiovascular disease 
mortality rate in South Africa, a survey reveals a deteriorating pattern for 
cardiovascular risk (Steyn et al., 1991, Mollentze et al., 1995), because of 
exposure to ongoing demographic transition and aggressive marketing of 
unhealthy consumer products.  Steyn et al. (1992) reported that in 1988 
ischaemic heart disease and cerebrovascular disease accounted for 9.6% 
and 7.9% respectively of deaths of all South Africans aged 35 - 64 years. 
This indicates a loss in the most productive sector of the labour force and 
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clearly constitutes a major cost to the economy.  Increasing urbanisation, 
the adoption of a westernised lifestyle and concurrent emergence of 
associated diseases in black South Africans seem set to further increase 
the national cost of cardiovascular disease.  The other reason for the 
deteriorating pattern of risk is the lipodystrophy associated with HIV 
antiretroviral treatment (Law et al., 2003; Miller et al., 2003).  The link 
between antiretroviral treatment and coronary heart disease is not dealt 
with in this dissertation; it is only mentioned to illustrate the future impact. 
 
2.4 RISK MARKERS FOR ATHEROSCLEROSIS AND THROMBOSIS 
 
The aetiology of ischaemic heart disease appears to have two 
components: a thrombotic component and a dietary fat/blood lipid 
component (Packham & Kinlough-Rathbone, 1994).  Any agent that 
damages or removes the endothelium can initiate or exacerbate 
atherosclerotic lesions, particularly when circulating cholesterol levels are 
high.  Injurious agents may synergize with each other.  Some of the agents 
that have been shown to damage the vessel wall also increase the 
sensitivity of platelets to aggregating agents, or activate the coagulation 
mechanisms, leading to the formation of thrombi.  In the absence of an 
unequivocal ante mortem diagnosis, factors which have been identified 
epidemiologically with the risk of coronary heart attack are examined. 
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Thus the haemostatic process; followed by the haemostatic, lipid and other 
risk markers will be discussed in the next section of this chapter. 
 
2.4.1 The haemostatic process 
Haemostasis, the spontaneous arrest of blood from ruptured vessels, 
involves the interaction of the damaged vessel wall, the blood platelets, 
and circulating blood coagulation factors that form a localised stable 
mechanical seal that subsequently undergoes slow removal by fibrinolysis 
(Ratnoff & Forbes, 1996), as depicted in Figure 2.1. 
 
VASCULAR INJURY 
 
     exposed   exposed 
     subendothelium  tissue factor 
 
 Vasoconstriction        Platelet aggregation  Coagulation 
 
            Clot formation 
 
     Fibrinolysis 
 
HAEMOSTASIS 
Figure 2.1 Overview of haemostasis, adapted from Ratnoff & Forbes 
(1996). 
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The haemostatic system is designed to maintain blood in a fluid state 
under physiological conditions but primed to react to vascular injury in an 
explosive manner to stem blood loss by sealing the defect in the vessel 
wall (Ratnoff & Forbes, 1996).  Rapid, localised haemostasis is achieved 
by complicated systems of activation and inhibition whereby excessive 
bleeding and unwanted thrombosis is minimised (Hutton et al., 1999).  The 
explosive cellular and molecular reaction is modulated by endothelial cell 
elaboration of antithrombotic lipids, proteins, inorganic compounds and 
several plasma proteases (Kemball-Cook et al., 2004). 
 
2.4.1.1 Vascular endothelium 
Normal vascular endothelium maintains blood fluidity by producing 
inhibitors of blood coagulation and platelet aggregation, modulating 
vascular tone and permeability, and by providing a protective envelope 
that separate haemostatic blood components from reactive sub-
endothelial structures (Kemball-Cook et al., 2004).  It modulates 
fibrinolysis by synthesising and secreting tissue plasminogen activators 
and plasminogen activator inhibitors (Ratnoff & Forbes, 1996).  Damage 
to a blood vessel exposes the elastin and collagen fibres in the 
supporting external layers that provide the principle stimulus.  Endothelial 
disruption activates all four components of the haemostatic apparatus: 
rapid vasoconstriction, platelets adherence and aggregation, coagulation 
and fibrinolysis (Hutton et al., 1999). 
 13
 
2.4.1.2 Platelets 
Platelets do not adhere to normal vascular endothelial cells.  However, 
an area of endothelial disruption provides binding sites for the adhesive 
proteins (Watson & Harrison, 2004).  Platelets adhere first to the basal 
layer of adherent platelets and eventually to one another, forming a mass 
of aggregated platelets (Hutton et al., 1999).  There is also release of 
platelet content that potentiates platelet aggregation.  During activation, 
platelets expose receptors for specific plasma clotting factors, particularly 
activated factor V (Va), which may be either secreted and expressed by 
platelets or bound from plasma.  This 'acquired' receptor in conjunction 
with anionic phospholipids exposed on activated platelets provides an 
efficient surface for coagulation (Hutton et al., 1999). 
 
2.4.1.3 Coagulation 
The process of coagulation occurs in a series of complex steps, involving 
various coagulation enzymes and factors, which terminate in the 
formation of the blood clot (Kemball-Cook et al., 2004).  Although it has 
been traditional to divide the coagulation system into intrinsic and 
extrinsic (tissue factor) pathways, such a division does not occur in vivo.  
The principal initiating pathway of in vivo blood coagulation is the tissue 
factor system, which involves components from both the blood and 
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vascular elements (Ratnoff & Forbes, 1996), as summarised in Figure 
2.2. 
 
 
 
 
 
 
 
 
 
Figure 2.2 Integrated in vivo haemostasis. All these processes, plus 
platelet activation occur simultaneously, with a short lag time. 
Inhibited complexes are shown in cartouches; dotted lines = 
proteolytic activation/inactivation; solid arrows = change of 
state; and the hatched underline = phospholipid surface upon 
which activator complexes assemble (Hutton et al., 1999). 
 
2.4.1.3.1 Fibrinogen 
Fibrinogen as a soluble glycoprotein has a molecular weight of 
340,000 Daltons and is present in high concentration in both plasma 
and platelet granules (Hutton et al., 1999).  The fibrinogen gene 
cluster is located on chromosome 4 q 31 in the order γ α β with β 
transcribed in the opposite direction to γ and α.  The overall structure 
of fibrinogen is a symmetrical dimer α2 β2 γ2 (Kemball-Cook et al., 
2004).  The molecule is trinodal with the outer two globular domains 
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(fragment D) containing the carboxytermini of all three chains, 
connected to the central globular domain (fragment E), which contains 
the N-termini (where fibrinopeptide A and B are found) of all the 6 
chains tethered together by disulphide bonds.  The lateral and central 
globular domains are connected by soiled coil region, forming α-helical 
ropes (Hutton et al., 1999). 
 
2.4.1.3.2 Fibrin network formation 
The precursor of fibrin is fibrinogen, which interacts with other 
proteins, including factor XIII, fibronectin, α2-antiplasmin inhibitor, 
plasminogen, and plasminogen activator (Hutton et al., 1999). 
Polymerisation of fibrinogen occurs when thrombin, which binds to the 
central domain, cleaves two short negatively charged fibrinopeptides A 
and B from the N-termini of the α and β chains respectively, resulting 
in the formation of a transient intermediate, termed fibrin monomer 
(Hutton et al., 1999).  Fibrinopeptide A is released more rapidly from 
fibrinogen than fibrinopeptide B, but as polymerization to protofibrils 
proceeds, the rate of fibrinopeptide B release is increased nearly 
sevenfold (Kemball-Cook et al., 2004).  This reveals new N terminal 
sequences in the fragment E region (called knobs) which fit into holes 
in the fragment D regions.  Polymerisation then occurs spontaneously 
in a half overlap array, which can elongate indefinitely in either 
direction (Ratnoff & Forbes, 1996). 
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Release of either set of fibrinopeptides initially leads to a half-
staggered overlap structure.  The structure is stabilised by non-
covalent interactions between complementary polymerisation sites 
present on the central and outer domains of the fibrin (Kemball-Cook 
et al., 2004).  Continuing thrombin-catalysed cleavage of the 
fibrinopeptides from the central domain of fibrinogen leads to the 
formation of two-stranded polymers of fibrin, termed protofibrils, in a 
rapid bimolecular polymerisation process.  Protofibrils' additional 
stability is provided by non-covalent interactions between the distal D 
domains of fibrin molecules aligned end-to-end in the same strand of 
each protofibril (Ratnoff & Forbes, 1996).  Progressive lengthening of 
the polymer chain occurs by a half-overlap, side-to-side approximation 
of fibrin monomer molecules, and the two-stranded protofibrils interact 
laterally to form either long, thin fibrin strands or short, broad sheets of 
fibrin.  In mature forms the fibrin fibre contains about 100 protofibrils, 
with a somewhat random pattern of branching that links the fibres 
together (Ratnoff & Forbes, 1996). 
It is suspected that the degree of lateral strand association probably 
contributes to the tensile strength of the clot.  Clot resistance to 
plasmin degradation is believed to be influenced mainly by 
crosslinking, mediated by Factor XIII (Doolittle, 1994).  In the early 
stages of the fibrin assembly process, protofibrils are stabilised by the 
factor XIIIa-catalysed formation of crosslinks between the γ-chains (D 
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domains) of the assembling fibrin molecules (Doolittle, 1994).  After 
pairing of virtually all the γ-chains in the fibrin network, a slower 
process of multiple crosslink formation between α-chains proceeds.  
These interwoven α-chain bonds are probably more critical for clot 
lysis resistance than is the limited geometry of the γ-γ crosslink.  
Factor XIIIa also covalently crosslinks α2-antiplasmin, the principal 
fibrinolytic inhibitor, to α-chains in the clot, thereby increasing 
resistance to degradation (Ichinose, 1994). 
 
2.4.1.4 Fibrinolysis 
The fibrinolytic system removes unwanted fibrin deposits to re-establish 
flow in vessels occluded by a thrombus and to facilitate the healing 
process following inflammation and injury (Hutton et al., 1999).  Although 
only a small proportion of plasma plasminogen is bound to fibrin during 
particulate clot formation, this is sufficient to influence subsequent 
physiologic breakdown of the clot (Kemball-Cook et al., 2004).  The 
process is a balanced one, involving plasminogien activator inhibitor-1 
and α2 -antiplasmin (Gaffney & Longstaff, 1994). 
 
2.4.2 Haemostatic risk markers and factors 
Hypercoagulability can be broadly defined as a risk of thrombosis in 
circumstances that would not cause thrombosis in a normal subject 
(Schafer, 1994).  From a clinical standpoint, patients suspected of having 
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a hypercoagulable state can be divided into two broad categories 
(Schafer, 1994).  The first category is the primary hypercoagulable state, 
with a specific defect in heparin-antithrombin III, protein C-thrombomodulin 
and protein S, or plasminogen-plasminogen activator mechanisms 
(Walker, 2004).  The second category consists of a heterogeneous array 
of clinical disorders in which there is an apparent increased risk for 
developing thrombotic complications as compared to the general 
population, for example, lupus anticoagulant, diabetes mellitus and obesity 
(Schafer 1994). 
 
2.4.2.1 Fibrinogen as a risk factor for CHD and CVD 
Prospective epidemiological studies have reported strong positive 
relationships, between fibrinogen level and the risk of myocardial 
infarction and/or stroke (Wilhelmsen et al., 1984, Stone & Thorp, 1985, 
Meade et al., 1986, Kannel et al., 1987, Heinrich et al., 1991, Møller & 
Kristensen, 1991).  The authors concluded that a high fibrinogen level 
was an independent risk factor for cardiovascular disease and that 
fibrinogen plays an especially important role in the thrombotic process, 
thus in the pathogenesis of cardiovascular disease (Figure 2.3).  It should 
be taken into account that the thrombotic tendency is unlikely to be 
accounted for by a single component of the haemostatic cascade, due to 
the complex pathophysiology of thrombosis.  Many studies have found a 
strong positive association between smoking and fibrinogen level, with 
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smokers having the highest fibrinogen levels, moderate levels among ex 
smokers and the lowest levels in non-smokers (Kannel, 1997; 
Wilhelmsen, 1988; Møller & Kristensen, 1991). 
 
 
Figure 2.3 Summary of potential mechanisms by which increased plasma 
fibrinogen levels may promote arterial disease and ischaemic events. 
LDL=low density lipoprotein (Lowe, 1993) 
 
2.4.2.2 Fibrin network architecture 
It is suspected that not only the fibrinogen concentration but also the 
quality of fibrin networks may contribute to CHD risk (Blombäck et al., 
1992).  It is found that fibrin clots composed of dense fibre networks are 
found in young coronary artery disease patients (Mills et al., 2002) and 
that their healthy male counterparts have clots with thicker fibres.  Fibrin 
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networks formed from plasma of the healthy controls are more 
permeable (Mills et al., 2002). 
Vascular occlusive disease has a higher incidence in the diabetic patient 
compared to the non-diabetic (Ostermann & van de Loo, 1996).  Nair et 
al. (1991) found that in the diabetic patient the fibre thickness (measured 
as the ratio of mass-length of the fibres) and permeability of networks are 
reduced.  These networks are also more resistant to lysis. 
It is known that any given network comprises of a major network of 
thicker fibres and a minor network of thinner fibres.  The minor network 
occupies the interstitial spaces between the major fibres (Nair et al., 
1986).  According to Blombäck et al. (1992) kinetic and modulating 
factors determine the dimensional gel structures.  Kinetic factors include 
the thrombin and fibrinogen concentration, while modulating factors 
include proteins and ions in close contact with the fibrinogen molecule 
(Blombäck et al. 1992).  
Three independent methods are used to characterize the fibrin network 
architecture.  The mass-length ratio serves as a measure of fibrin 
thickness (Nair et al., 1991). Permeability serves as a measure of 
variability in fibrin fibre thickness and pore size within the network, which 
indicates the degree to which fluids can move through the network and 
therefore carry enzymes that support the breakdown of the network, 
especially of unwanted clots (van Gelder et al., 1995).  Compaction 
characterises the degree of cross-linking and tensile properties of the 
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fibrin network (Nair & Shats, 1997). Other techniques include the network 
lysis rate, which could be used to assess the overall structure of the fibrin 
network in terms of lytic rate under controlled conditions.  Gabriel et al., 
(1992) have shown that thin fibrin fibres are lysed more slowly when 
compared to thick fibrin fibres.  
It is suggested that fibrin networks with mostly thin fibres, decreased 
permeability and higher tensile strength are more atherogenic in nature 
(Blombäck et al., 1992).  Fibrin networks with mostly thicker fibres, which 
are more permeable and have lower tensile strength, are believed to be 
less atherogenic.  This is because they are more deformable, allow easy 
access of the lytic enzymes and also have greater exposed surface 
areas for the fibrinolytic agents (Blombäck et al., 1992). 
 
2.4.2.3 Factor VII 
A high blood factor VII activity level has been reported to predispose 
patients to the onset of ischaemic heart disease (Meade et al., 1986, 
1986a).  Surgue et al. (1985) demonstrated that in a series of patients 
with heterozygous familial hypercholesterolaemia, the age adjusted 
mean plasma fibrinogen level and factor VII activity were significantly 
higher in patients with evidence of CHD when compared to patients 
without CHD.  Serum lipids concentration did not differ significantly 
between the two groups. Heinrich et al. (1994) reported that there is a 
trend toward higher factor VII activity and occurrence of CHD events. 
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Meade et al. (1986) postulated that dietary fat may be an important 
determinant of factor VII activity.  Miller et al. (1986) found a positive 
correlation between dietary cholesterol intake and factor VII activity.  
Factor VII is assumed to be activated via the negative charge of 
chylomicrons and VLDL.  Accordingly, dietary intake of fats could 
influence the risk of ischaemic disease via a long term atherogenic and a 
short-term thrombogenic pathway.  Since factor VII activation leads to an 
increase in thrombin concentration, thereby intensifying platelet activation 
and procoagulatory mechanisms, it can be assumed that, conversely, 
cholesterol-lowering measures also reduce the thrombotic risk 
associated with a high activity of factor VII (Miller et al., 1986). 
 
2.4.2.4 Factor VIII 
Since factor VIII and von Willebrand factor are both procoagulants, 
favouring clot formation and platelet adhesion, high levels might be 
expected to be risk factors for thrombosis and atherosclerosis.  Conlan et 
al. (1993) showed a strong association of factor VIII with a number of 
known cardiovascular disease risk factors.  Pan et al. (1997) found a 
positive association between factor VIII concentration and carotid 
atherosclerosis in the Chinese population.  The authors suggest that the 
association might not be independent.  In the Northwich Park Heart 
Study, the individuals in the highest tertile group of factor VIII levels were 
associated with a 44% increase in risk for CHD (Meade et al., 1986).  
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Meade et al. (1986a) found that factor VIII was highest in Africans than 
Caucasians as observed in other studies (Conlan et al., 1993).  It is 
suggested that factor VIII levels may be determined predominantly by 
genetic (ethnic group and ABO status) rather than environmental 
characteristics. 
 
2.4.2.5 Fibrinolytic factors 
A variety of fibrinolytic defects have been implicated in the pathogenesis 
of thrombosis.  These include decreased release of tissue plasminogen 
activator (Nilsson et al., 1985) and increased plasminogen activator 
inhibitor -1 (PAI-1) concentration (Hamstern et al., 1987).  The net effect 
of each of these abnormalities is impaired functional plasmin generation 
and a blunted fibrinolytic response to fibrin formation (De Pergola & 
Pannacciulli, 2002).  High PAI-1 levels may be markers that help identify 
individuals with an increased risk of recurrent myocardial infarction 
(Hamstern et al., 1987). 
 
2.4.2.6 Platelets as a risk factor for CHD and CVD 
The development of thrombosis, especially arterial, is greatly influenced 
by platelets.  This is important where vessel disease, especially 
atherosclerosis, is the underlying cause.  Platelet hyperaggregability is 
associated with increased risk of cardiovascular incidence (Mammen, 
1999).  This is particularly true for sticky platelet syndrome, where 
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platelets show marked hyperaggregability with ADP and/or epinephrine 
(Mammen, 1995; Frenkel & Mammen, 2003).  These patients have an 
increased risk of developing thrombosis, even while on anticoagulant 
therapy or with no evidence of other hyperaggregability conditions. 
 
 
2.4.3 Lipid risk markers 
A total plasma cholesterol level above 5.2 mmol/l is considered to promote 
the development of advanced atherosclerotic lesions (Roberts, 1989; 
Oliver, 1990).  The Lipid Research Clinics Coronary Primary Prevention 
Trial (1984 a & b) and Helsinki Heart Study (Frick et al., 1987), clearly 
showed that lowering plasma cholesterol levels brings benefit in terms of 
reduction of coronary morbidity.  High cholesterol levels have also been 
reported to result in platelet hypersensitivity to aggregating agents in man 
(Bradlow et al., 1982; DiMinno et al., 1986).  The question of whether 
elevated levels of plasma triglycerides are an independent risk factor for 
coronary heart disease is unsettled and controversial (Oliver, 1990; Austin, 
1991; Criqui, 1991; Wilson et al., 1991).  It is hypothesised that the risk for 
coronary artery disease associated with blood cholesterol increases with 
rising plasma concentrations of LDL-C.  However, it is also believed that 
the risk associated with LDL-C is diminished when associated with high 
HDL-C concentrations.  For this reason, some laboratories calculate the 
ratio of LDL-C: HDL-C for estimating the degree of risk; a ratio of less than 
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3:1 is considered desirable (Kaplan et al., 1995).  The LDL:HDL ratio is a 
strong predictor of cardiac events (Hermansen et al., 2003). 
 
2.4.3.1 Lipoprotein classes 
Cholesterol, plasma phospholipids, triglycerides and other hydrophobic 
fats, enter and leave plasma bound to specific proteins, forming 
lipoproteins (Kaplan et al., 1995).  The protein and phospholipids impart 
solubility to the otherwise insoluble lipids.  Apolipoprotein (apo) are 
protein moieties of the lipoprotein.  The lipoproteins act as carriers of 
triglyceride.  Lipoproteins can be classified as chylomicrons, very-low 
density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), the 
low-density lipoprotein (LDL), or high-density lipoprotein (HDL).  Each of 
these lipoprotein families contains cholesterol, but in differing 
proportions.  Chylomicrons, for example, which are more than 95% 
triglyceride by weight, carry 1% cholesterol and less than 1% protein. 
VLDL, in contrast, contains about 10% protein, 18% cholesterol by 
weight, and has fivefold more triglycerides compared to cholesterol. LDL 
contains 50% cholesterol by weight; while HDL has 50% protein by 
weight and an estimated 23% cholesterol content (Kaplan et al., 1995). 
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2.4.3.2 Low-density lipoprotein cholesterol (LDL-C) 
LDL-C binds to specific primary receptors on fibroblasts, which are 
responsible for their transport into the cell (Levy, 1981).  In humans the 
concentrations of LDL-C in the bloodstream totally saturate the primary 
LDL-C receptor sites in vivo.  Other non-specific receptors become 
involved in the clearance of lipoprotein - including receptors on the lining 
of the blood vessels themselves, where cholesterol accumulates.  It is 
postulated that the reason humans are susceptible to atherosclerosis is 
because our LDL-C concentrations are higher and above the threshold of 
primary clearance (Levy, 1981). 
Two main LDL-C phenotypes have been identified, one characterised by 
the predominance of large buoyant LDL-C particles and other by an 
excess of small, dense LDL-C particles.  A pattern consisting of an 
increased concentration of small, dense LDL-C particles, an elevation of 
triglycerides and a reduction in HDL-C has been shown to increase the 
risk of ischaemic cardiac events (Halle et al., 1996). 
 
2.4.3.3 High density lipoprotein cholesterol (HDL-C) 
There exists a negative association between HDL-C and the incidence of 
ischemic heart disease (Stampfer et al., 1991).  A circulating HDL-C 
concentration of less than 35 mg/dl (approximately 0.85 mmol/L) is 
believed to promote the onset of atherogenesis, while a higher 
concentration of the molecule is believed to offer protection against 
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atherosclerosis.  HDL-C is not monodisperse, but exists as two main 
populations, designated HDL2 and HDL3. Of the two, HDL3 is major and 
HDL2 minor in mass terms, but not in clinical significance (Cheung et al., 
1991). 
 
2.4.3.4 Dietary fat and lipid metabolism 
The interplay between diet and lipid metabolism has been the topic of 
investigation for many decades.  Both randomised clinical trials and long-
term epidemiological studies were used to investigate possible 
relationships between dietary fat intake and lipid metabolism.  Diets rich 
in saturated fatty acids of chain length 12 to 16 carbons not only raise 
circulating total cholesterol levels (Ulbright & Southgate, 1991), but have 
also been shown to be thrombogenic in rats and in man.  It is believed 
that polyunsaturated fatty acids are antithrombotic in nature (Hornstra, 
1980, 1989; NordØy & Goodnight, 1990).  It has been pointed out that 
the ratio of polyunsaturated to saturated fatty acids (P/S ratio) in the diet 
also influences platelet function in man (Renaud, 1990).  Renaud (1990) 
noted that a dietary P/S ratio of 0.7 is characteristic of the Japanese diet, 
a population in whom the clinical complications of atherosclerosis are 
reduced.  Enrichment of diets with omega-6 polyunsaturated fatty acids 
has been shown to depress serum-HDL-C levels, as well as lowering the 
LDL-C (Ulbright & Southgate, 1991).  Trans-polyunsaturated fatty acids 
(produced during the hydrogenation of liquid vegetable oils), in contrast 
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to cis-polyunsaturated fatty acids, have been found to raise LDL-C levels 
and lower HDL-C levels in man (Mensink & Katan, 1990), and hence are 
considered to be atherogenic.  A diet low in saturated and trans-fatty 
acids, with adequate amounts of monounsaturated and polyunsaturated 
fatty acids, especially long-chain omega-3 fatty acids, would be 
recommended to reduce the risk of developing CHD (Lichtenstein, 2003). 
 
 
2.4.4 Other cardiovascular risk factors 
Other risk factors generally associated with increased cardiovascular risk, 
include: 
• Smoking status (Hennekens et al., 1984; Haapanen et al., 1989; 
Homer et al., 1991; Ingall et al., 1991),  
• Obesity (Lowe et al., 1988; Lee et al., 1990; Lowe et al., 1992; De 
Pergola & Pannacciulli, 2002),  
• Diabetes mellitus (Colwell, 1988; Ostermann & van de Loo, 1996),  
• Hypertension (Kannel, 1991),  
• Stress, or type A personality (Siltanen, 1987; Dimsdale, 1988),  
• Adrenaline and noradrenaline (Hourani & Cusack, 1991),  
• Hyper-homocysteinaemia (McCully, 1990; Clarke et al., 1991),  
• Gender (Beard et al., 1989; Stampfer et al., 1991a),  
• Physical inactivity (Powel et al., 1987; Møller & Kristensen, 1991; 
Kannel, 1997) and  
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• Age (Bush et al., 1988; Witterman et al., 1989; Barrett-Connor & 
Bush, 1991). 
 
 
2.5 PROPOSED DISEASE MECHANISMS 
 
Stroke and coronary heart disease are multifactor diseases.  Their 
sequelae encompass genetic factors; physiological factors, such as 
metabolism of the arterial wall; humoral factors, including lipids and 
lipoproteins and the complex mechanics of blood clotting; stress and 
psychological factors; and ecological factors which include diet and 
behaviours such as cigarette smoking (Ulbright & Southgate, 1991).  
Stroke and CHD commonly involve atherosclerosis and thrombosis thus 
the following section will be used to supply a detailed description of 
thrombogenesis and atherogenesis. 
 
2.5.1 Thrombogenesis 
A thrombus is a deposit formed from blood constituents on the surface of 
the heart lining or blood vessels, and can occur anywhere in the circulation 
(Summers et al., 2004).  In 1856 Virchow proposed that three major 
factors determine the site, kind and extent of a thrombus: first is the 
mechanical effect in which blood flow is predominant; second is alterations 
in the constituents of blood; and thirdly, changes in the vessel wall 
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(Packham & Kinlough-Rathbone 1994).  Thrombosis and blockage of 
narrowed arteries is a fatal event and the cause of more than 90% of 
deaths from CHD (Polk, 1985).  Thus, the partially occluded artery is easily 
blocked by thrombi formed from aggregated platelets or white blood cells 
that rapidly aggregate and clump in response to specific stimuli (Polk, 
1985; Ross, 1986; Kinsella et al., 1990). 
Vascular damage initiates activation of platelets and the coagulation 
cascade that is fundamental to thrombus formation.  Aggregation is 
induced by thromboxane A2 (Kinsella et al., 1990).  Arterial thrombi are 
stabilised by the following: 
• adhesive blood proteins 
• the granules of platelets that have released their granule contents, 
• ADP from platelet dense granules or from red blood cells, and  
• by fibrin formed under the influence of thrombin.  
 
In addition, clot retraction mediated by platelet actomyosin consolidates a 
thrombus and makes it less susceptible to fibrinolysis (Fitzgerald, 1991). 
 
2.5.2 Atherogenesis 
Atherosclerotic lesion formation can be induced in two ways: by enriching 
the diet with cholesterol (or saturated fats) (Armstrong & Heistad, 1990) or 
by repeated injury of the wall of the artery of normocholesterolaemic man 
or animals (Tyson et al., 1976; Moore, 1981).  The theory of repeated 
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injury is supported by re-occlusion of vessels and accelerated 
development of atherosclerotic lesions after procedures such as bypass 
surgery, angioplasty and endarterectomy (Summers et al., 2004).  Injury-
induced atherosclerosis is exacerbated by lipid-enriched diets (Minick, 
1981).  Atherosclerosis is a complex process so it is believed that both 
theories might play a role simultaneously. 
The suggested sequence of events is that monocytes adhere to the 
endothelium, migrate into the intima, and become macrophages that take 
up lipids.  Before uptake, low-density lipoprotein cholesterol (LDL-C) is 
oxidised, either in or adjacent to endothelial cells, or when it is bound to 
proteoglycans in the intima.  Furthermore, it is shown that extensive 
oxidation of LDL-C leads to its aggregation (Moar et al., 1997).  Both of 
these modified forms of LDL-C are present in the atherosclerotic lesion 
(Aviram et al., 1995).  Following infiltration, macrophages phagocytose the 
cholesterol rich LDL-C particles (especially when oxidised or modified), 
mediated by scavenger receptors on the macrophage membrane (Aviram 
& Fuhrman, 1998).  Foam cells are formed.  The macrophages secrete 
growth factors, thereby stimulating the proliferation and migration of 
smooth muscle cells (Steinberg, 1988, 1992; Esterbauer et al., 1992).  
Other sources of growth factors include the endothelial cells and the 
smooth muscle cells (Ross, 1989; Gordon et al., 1989; Clowes, 1991).  
Over time, these lipid-laden cells progressively accumulate and the 
adjacent smooth muscle cells proliferate, causing the formation of a raised 
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lesion (Ross, 1986; Steinberg, 1988; Kinsella et al., 1990).  Eventually, the 
endothelium is disrupted over the foam cells.  At this stage platelets 
adhere and are induced to secrete growth factors, which further stimulate 
the migration and proliferation of smooth muscle cells (Faggiotta & Ross, 
1984; Masuda & Ross, 1990).  Gradually the lesion develops into a fibrous 
plaque.  The calcification of advanced lesions may occur. Ultimately, 
plaque impedes blood flow.  There is growing evidence that oxidation 
and/or modification of the lipids contained within LDL-C greatly increase 
the capacity of macrophages, endothelial cells, and monocytes to bind and 
ingest oxidised LDL via receptors, thus accelerating atherogenesis (Ross, 
1986; Steinberg, 1992).  
 
 
2.6 DIETARY FIBRE 
 
In 1885 Louis Pasteur suggested that the presence of bacteria in the 
alimentary tract was essential for the life of rabbits and guinea pigs, 
although this suggestion was subsequently disproved by the successful 
rearing of germ-free specimens of these animals.  Their shortened survival 
supported the principle that the intestinal flora is important for normal 
nutrition (Wrong, 1995). 
Dietary fibres from natural or semi-synthetic sources have gained 
increasing attention because of their value as a supplement to the normal 
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western diet, which is poor in bulking substances.  Addition of fibre for 
treatment of disorders such as atherosclerosis and colon cancer could 
hold therapeutic value (Wrong, 1995). 
 
2.6.1 Short chain fatty acids (SCFAs) 
Short chain fatty acids are the end product of microbial fermentation within 
the digestive tract.  Those of interest to us can be described as "saturated 
unbranched alkyl monocarboxylic acids of 2 - 4 carbon atoms" (Wrong 
1995).  SCFAs (acetate, propionate & n-butyrate) and gases (H2, CH4 & 
CO2) are the main end products of the anaerobic breakdown of complex 
polysaccharides by colonic bacteria (Bourquin et al., 1992a).  SCFAs 
make up the predominant anions in the large intestine of mammals and 
create a slightly acidic pH level (6.0-7.0).  SCFAs vary widely in their 
relative proportions, depending upon the fibre source in the diet.  SCFAs in 
human faeces, following consumption of different defined polysaccharides, 
have been measured on average, in the molar ratio of acetate: propionate: 
butyrate of 53: 27:20 (Brøbech-Mortensen & Clausen, 1996). 
 
2.6.2 Fermentation 
"Fermentation" in the human large intestine is used to describe the great 
variety of reactions and the overall metabolic process involved in the 
anaerobic breakdown and partial mineralization of organic matter, 
catalysed by microbial enzymes (Macfarlane & Gibson, 1995).  The 
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microbial populations in the large intestine are composed of several 
hundred different micro-organism species (prokaryotes and eukaryotes).  
In general, most individuals within the same racial and socio-economic 
groups harbour similar cell population densities and generic distribution of 
bacteria in their colons (Macfarlane & Gibson, 1995). 
Substrate for microbial fermentation in the large intestine are 
macromolecules that come from endogenous (sloughed epithelial cells, 
lysed microbial cells, mucus, and other intestinal excretion) and 
exogenous (mostly fibrous components of food) sources, that cannot be 
digested by host enzymes (Brøbech-Mortensen & Clausen, 1996).  The 
major substrates include polysaccharides, non-starch polysaccharides 
from plant cell walls, dietary proteins and peptides (Macfarlane & Gibson, 
1995).  Dietary fibres are complex polysaccharide polymers that derive 
from plant cell walls.  The structure is made up of water-insoluble cellulose 
microfibrils coated with soluble hemicellulose and embedded in a gel of 
pectins.  Variable amount of starch that escape digestion in the small 
intestine (this fraction is called resistant starch) also pass into the colon 
and become available as substrate for microbial fermentation, as does 
dietary fibres (Brøbech-Mortensen & Clausen, 1996). 
The more predominant factors that affect SCFA production from 
polysaccharides and protein by bacteria in the large intestine are as 
follows:  
• chemical composition of the fermentable substrate;  
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• amount of substrate available;  
• type of bacteria present in the large gut;  
• rate of depolymerization;  
• colonic transit time;  
• availability of inorganic electron acceptor;  
• pH of the gut content, particularly in the proximal colon;  
• fermentation strategies of substrate-utilising bacteria;  
• substrate specificities and catabolite regulation mechanism of 
individual competitive and co-operative particle size;  
• solubility and association with indigestable complexes such as 
lignins, tannins and silica (Macfarlane & Gibson, 1995). 
 
2.6.3 Absorption 
There is ample evidence that SCFAs are rapidly absorbed from the colonic 
lumen. Cummings (1981) suggested that, on the basis of a typical western 
diet containing 20g fermentable carbohydrate, 200 mmol SCFA are 
produced by colonic anaerobic bacteria; 90-97% (180-193 mmol) of SCFA 
are absorbed and only 3-10% (7-20 mmol) are excreted in faeces 
(Scheppach et al., 1987; Brøbech-Mortensen & Clausen, 1996).  Several 
models have been proposed to explain SCFA transport (Engelhardt, 1995) 
and to account for the large number of observations describing the 
dependence of SCFA absorption rates on luminal pH and pCO2 , as well 
as on fluxes of water, protons, and inorganic ions (Cl-, HCO3-, Na+ and K+) 
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through the mucosa.  SCFAs may also be transported in the ionised form 
via an SCFA- HCO3- exchange mechanism. 
SCFA absorption in the large intestine involves several processes: non-
ionic diffusion, carrier-mediated mechanisms, diffusion after protonation, 
carrier mediated SCFA anion exchange with bicarbonate, and diffusion 
coupled with sodium absorption (Scheppach et al., 1987).  It is widely 
believed that the transmural movement of SCFAs is a concentration-
dependent, passive diffusion process, whereby SCFAs, at least in part, are 
transported in the protonated form.  Hydrogen ions are needed for SCFA 
protonation, because 99% of SCFA (pKa = 4.8) are in the ionised form for 
hydration of luminal CO2 to HCO3- and H+.  In addition, the mechanism of 
uptake into enterocytes is undoubtedly a complex process involving a 
number of factors and mechanisms (Engelhardt, 1995).  The precise 
mechanism for the absorptive process of SCFAs remains undefined, but 
all these above outlined factors seem to play a role (Brøbech-Mortensen & 
Clausen, 1996). 
 
2.6.4 Metabolism 
Butyrate is found in lower proportion in the blood draining the large 
intestine when compared to blood draining the lumen (Brøbech-Mortensen 
& Clausen, 1996).  This reflects the fact that a large part of absorbed 
butyrate is metabolised by the mucosa (to carbon dioxide and ketone 
bodies).  Butyrate is an important fuel for the colonic mucosa whereas 
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acetate and propionate are released into the portal blood.  Portal vein 
concentrations of butyrate are approximately tenfold higher when 
compared to the peripheral vein concentration, while propionate 
concentrations are 20 - 40 folds higher and acetate concentrations only 
approximately fourfold higher.  The major site of SCFA metabolism is the 
liver; where butyrate and propionate are almost entirely absorbed.  
However, the percentage of acetate uptake is lower (frequently less than 
50%).  SCFA concentrations in the portal vein are closely dependent on 
digestive fermentation (Brøbech-Mortensen & Clausen, 1996). 
Hepatic butyrate uptake is practically total under physiological conditions.  
Butyrate is exclusively metabolised in mitochondria (carnitine-independent 
source of acetyl-CoA) and act as a potentially ketogenic substrate during 
the post-absorptive period.  In fed subjects, butyrate may represent a 
precursor for lipogenesis.  High concentrations of butyrate inhibit 
propionate utilisation.  Because of the provision of acetyl-CoA in 
mitochondria, butyrate is an effective activator of gluconeogenis from 
lactate, and of ureogenesis; thus butyrate probably thwarts some of the 
inhibitory effects of propionate on gluconeogenesis (Rèmésy et al., 1995). 
Under healthy conditions, propionate is totally taken up by the 
hepatocytes.  Propionate may depress the rate of ureogenesis, in contrast 
to acetate and butyrate that activate it.  Propionate is also a very effective 
gluconeogenic substrate in most species.  Propionate is probably a 
constituent precursor of glycogen synthesis and possibly of lipid synthesis. 
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It acts as an inhibitor of pyruvate oxidation in hepatocytes from fed rats.  In 
addition, propionate increases the release of lactate in hepatocytes from 
fed rats by increasing glycolysis.  This effect is counteracted by aleote, 
which suggests that propionate inhibits the production of acetyl-CoA and 
citrate (Rèmésy et al., 1995). 
The metabolic fate of acetate and its role in the liver is connected to the 
general orientation of metabolism towards carbohydrate or lipid utilisation.  
Acetate stimulates in vitro fatty acid synthesis but inhibits cholesterol-
genesis within isolated rat hepatocytes (Rèmésy et al., 1995).  
Furthermore, acetate can stimulate gluconeogenesis from lactate.  A 
substantial fraction of acetate from digestive fermentation is not taken up 
by the liver.  Splanchnic balance of acetate is always positive, even during 
fasting periods.  Most of the extrasplanchnic tissues can metabolise 
acetate, for example, adipose tissue, mammary gland (cytosolic), muscle, 
kidney, and the heart (mitochondrial).  These tissues have acetyl-CoA 
synthase.  The cytosolic localisation of acetyl-CoA synthase should 
channel acetate toward lipogenesis, whereas the mitochondrial localisation 
favours its utilisation for energy supply in the Krebs cycle (Rèmésy et al., 
1995). 
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2.6.5 Biological effects of SCFA 
Various epidemiological and case control studies have shown that the 
intake of dietary fibre has some beneficial effects on the health of human 
subjects (Brøbech-Mortensen & Clausen, 1996).  Especially the 
cholesterol-lowering effects of dietary fibre intake have been the topic of 
many studies.  The specific mechanism through which dietary fibre 
decreases blood cholesterol concentration is unclear.  Two possible 
hypotheses have been developed: (1) soluble fibres bind bile acids in the 
intestine, alter lipid and bile-acid absorption and increase faecal loss of 
bile acids; and (2) soluble fibres are fermented in the colon to short-chain 
fatty acids, which are absorbed into the portal vein and attenuate hepatic 
cholesterol synthesis (Anderson & Siesel, 1990). 
 
2.6.5.1 Butyrate 
The effect of butyrate on haemostasis is not known, while the effect on 
lipid metabolism has not been extensively studied.  In cultured cell lines, 
butyrate is a well-recognised antitumor agent, whereas the other SCFAs 
are much less active in this respect (Young & Gibson, 1995; Brøbech-
Mortensen & Clausen, 1996). 
  
2.6.5.2 Propionate 
Venter et al. (1997) undertook a study where baboons were fed a 
western diet with either a 2% propionate or 5% soluble dietary fibre 
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concentrate supplement.  Total serum cholesterol values were increased 
in the baboons fed an unsupplemented western diet.  Soluble fibre 
supplementation prevented this increase, while propionate did not.  
However, both propionate and fibre intake increased the serum high-
density-lipoprotein cholesterol concentration.  Furthermore, the liver 
cholesterol concentration was lowered by propionate and fibre 
supplementation.  Experimental studies in animals indicate that feeding 
oat bran has hypocholesterolaemic effects (Brøbech-Mortensen & 
Clausen, 1996).  Concomitant to this, oat bran significantly increases 
portal vein propionate concentration.  In comparison, cellulose that does 
not lower cholesterol levels does not increase the propionate 
concentration.  In vitro studies indicate that propionate at physiological 
concentrations, significantly decreases hepatic cholesterol synthesis 
(Anderson, 1995).  Other conflicting results show that propionate 
administered rectally, has no effect on either the circulating total 
cholesterol or the triglyceride concentration (Wolever et al., 1991).  When 
administered orally, propionate is reported to have no effect on serum 
cholesterol levels, but causes an increase in the triglyceride 
concentration (Brøbech-Mortensen & Clausen, 1996).  Conflicting results 
show that the total serum cholesterol concentration is slightly decreased 
and the triglyceride concentration slightly increased (Anderson, 1995). 
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2.6.5.3 Acetate 
When acetate is administered through different routes, for example oral, 
rectal and intravenous, to healthy human volunteers the following are 
found.  Decrease in glycerol levels and a significant decrease in serum 
concentrations of free fatty acids.  Acetate appears to compete with long-
chain fatty acids for oxidation in certain tissues, promote hepatic 
cholesterol synthesis and decrease lipolysis (Topping & Pant, 1995).  
Veldman et al., (1999) postulated that pectin and acetate effected a 
positive change in the fibrin network structure.  These changes are partly 
accounted for by the direct effect of acetate on fibrin network structure. 
 
2.7 SUMMARY OF LITERATURE REVIEW 
 
Cerebrovascular disease and coronary heart disease (CHD) are of the 
most important causes of morbidity and mortality amongst South Africans.  
The risk factor prevalence for stroke and CHD becomes altered by 
changes in lifestyle, including diet.  In general it is suggested that lifestyle 
management should be the first choice when having to treat patients with 
increased cardiovascular risk. 
The prudent low-fat, high-fibre diet is regarded as an apparently healthy 
diet.  It is suspected that this diet is effective for the control of known 
coronary risk factors as well as raised clotting factors.  Research studies 
have shown the addition of dietary fibre to the diet as a promising 
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therapeutic agent for the limited control of known coronary risk factors.  
The physiological effects of dietary fibre in humans are significantly 
influenced by the degree to which fibre is fermented in the colon.  
Fermentation results in the production of short-chain fatty acids (SCFAs) 
acetate, propionate and butyrate. 
This chapter has been used to show how CHD and stroke are related to 
lifestyle changes especially diet, and the reason why black people were 
chosen as the study population.  CHD and stroke involves both 
haemostasis and lipids.  Risk markers from both where discussed, to show 
a link between diet and these variables.  Finally, the short-chain fatty 
acids' link with haemostatic and lipid risk markers was discussed to 
explore the possible mechanism by which SCFAs affects the risk markers.  
Thus a foundation has been laid for the understanding of this study 
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CHAPTER 3 
 
MATERIALS AND METHODS 
 
3.1 INTRODUCTION 
 
In this study a group of westernised African male volunteers were recruited 
and fed two different combinations of short-chain fatty acids, as well as a 
placebo supplement, for a period of six weeks.  Blood was drawn at 
different intervals and analysed to assess changes that were brought 
about by the different supplements. The study was explained to all 
volunteers, where they signed the Informed Consent Document (appendix 
A) and completed the recruitment questionnaire (appendix B).  Blood 
sampling and medical examinations were performed at the medical 
facilities of the Tempe Military Base, Bloemfontein.  Laboratory analyses of 
samples were performed at the Research Laboratory, School of Health 
Technology, Central University of Technology, Free State. 
 
3.1.1 Ethical consideration 
This study proposal was submitted to and approved by the Ethics 
Committee of the University of the Free State, reference number: ETOVS 
227/98.  The study was conducted according to International Good Clinical 
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Practice Guidelines and adhered to the contents of the Declaration of 
Helsinki. 
 
3.1.2 Study design 
Volunteers were recruited from the Military Base at Tempe Defence Force, 
Bloemfontein, and randomly assigned to three different supplementation 
groups.  Group 1 received a placebo filled with non-fermentable cellulose.  
Group 2 received a supplement containing 50% acetate and 50% 
propionate.  Group 3 received a SCFA supplement in the ratio of 70% 
acetate, 15% propionate and 15% butyrate.  Neither researchers, field-
workers nor the volunteers were aware of which supplement they were 
assigned to.  The study was therefore double-blind. 
A calculation based on the results of previous experiments was only of 
partial value for obtaining sample size since effects of propionate 
supplementation on outcomes measured in this study were not available.  
For power calculations a reference of 15% change in circulating blood 
cholesterol was used (Veldman, 2000).  It was estimated that a group of 
25 individuals per supplement would allow for expected drop-outs without 
a significant loss of statistical power. 
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3.1.3 Work schedule 
A recruitment day was scheduled during which blood samples were drawn, 
dietary intake, social and geographic background questionnaires 
completed, as well as anthropometric measurements taken as part of the 
selection process.  The scientific value of the study and expectations of 
the researchers were also explained to the volunteer, in both English and 
their preferred mother tongue.  Inclusion criteria were strictly adhered to 
for selection of participants.  A total of 75 subjects were selected after 
scrutinisation of the recruitment data.  For standardisation purposes 
supplementation followed after a run-in phase of one week, during which 
all subjects consumed placebo supplements.  Subjects were then 
randomly assigned to one of three groups.  Blood was also drawn on day 
8 (end of the run-in phase) which also served as a baseline measurement.  
Volunteers then consumed the pellets containing different combinations of 
SCFAs or placebo corresponding to their group assignment for a period of 
four weeks.  A washout period of one week followed.  Blood samples were 
drawn after two weeks of supplementation on day 22, and again at the end 
of the four week period on day 36. Following day 36, all subjects 
consumed placebo containing capsules for seven days, after which blood 
was drawn to assess the recovery of measured variables after 
supplementation. At the end of the study the subjects completed a 
questionnaire about their experiences during the study (appendix C). 
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3.2 MATERIALS 
 
3.2.1 Study population 
Only seventy-five subjects met the inclusion criteria.  The subjects were 
permanent African male staff of Tempe Military base, Bloemfontein.  The 
inclusion criteria were as follows: 
• No smokers, alcoholics, and history of cardiovascular incidences 
• No usage of chronic medications 
• No usage of medication or other supplementation during the study, 
without the knowledge of the study leader 
• No lifestyle changes during study and at least six months prior to 
the study 
• Subjects should have been permanent staff for at least one year 
prior to the study 
• No familial hypercholesterolaemic subjects were used 
• Subjects should have a fibrinogen level of higher than 2.5 g/L in 
order to recognise significant effects on this variable. 
• The background diet should be identical and contain about 
15 grams unabsorbed carbohydrates. 
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3.2.2 Supplements 
Volunteers obtained SCFA supplements in capsules equivalent to the 
fermentation of 15 grams dietary fibre.  The capsules were designed in 
such a way that their contents were released only in the large intestine; 
they were resistant to stomach acid and small intestine enzymes (coated 
with a chelac-containing spray).  The reason for this was to simulate the 
generation of SCFA in the large intestine.  The supplements’ content, ratio 
and concentration were calculated using the sheet attached in appendix D.   
 
The acetate/propionate ratios were as follows: 
Group one: Placebo capsules containing indigestible cellulose. 
Group two: Half + half 50% acetate 50% propionate 0% butyrate 
Group three: High acetate 70% acetate 15% propionate 15% butyrate 
 
Compliance of supplement consumption was monitored by the dieticians 
(Captains M De Wet & A van Onselen – who were involved in the study), 
as the entire subject group ate their meals at the Mess-hall of Tempe 
Military Base, Bloemfontein. 
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3.2.3 Specimen collection 
Fasting samples were required thus venepuncture was performed 
between 8:00 and 10:00 am, and the subjects fasted from 22:00 the 
previous night.  For full blood count and C-reactive protein analysis, blood 
was drawn into 5 ml EDTA tubes.  Two 10 ml red top tubes were drawn for 
chemical analysis, and six full 5 ml tri-sodium citrate (3.8%) tubes were 
obtained for coagulation assays. 
3.2.4 Apparatus 
The apparatus used during the procedures were in good working condition 
and calibrated to give accurate results. 
 
	 	
	
		

Apparatus Description Brand name Supplier  
Coagulation analyser Coagulation Timer Berhring Dade Berhring 
Chemical analyser Hitachi 902 Hitachi Boehringer Mannheim 
Cell counter Coulter MD 18 Coulter Beckman Coulter 
Microplate reader EL 312e Biotek Biotek instruments 
CRP analyser MICROS CRP  ABX CRP-100 ABX diagnostics 
Spectrophotometer Shimadzu UV-1201 Shimadzu Scientific Group 
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3.2.5 Standards and controls 
 

 

	
	


Standard or control Catalogue no Supplier 
Fibrinogen Standards 1-4# OWCS 11 Dade Berhring, Marburg, Germany 
Standard Human Plasma# ORKL 17 Dade Berhring, Marburg, Germany 
Control Plasma N# ORKE 35 Dade Berhring, Marburg, Germany 
Control Plasma P# OUPZ 13 Dade Berhring, Marburg, Germany 
D-Dimer Standard Plasma# OQXA 11 Dade Berhring, Marburg, Germany 
D-Dimer Control Plasma I# OQKA 15 Dade Berhring, Marburg, Germany 
D-Dimer Control Plasma II# OQKB 17 Dade Berhring, Marburg, Germany 
S.F.A.C.* 759350 Roche Diagnostics, Mannheim, Germany 
Percinorm® U* 171735 Roche Diagnostics, Mannheim, Germany 
Percipath® U* 171760 Roche Diagnostics, Mannheim, Germany 
#
 the reagents used for calibration and control of coagulation assays, while * where used 
for chemical assays. 
 
 
3.2.6 Reagents and consumables 
The reagents and some consumables which were used during the study 
are listed in the following table. 
 
 

	
	
	
	
Reagents & consumables Catalogue no Supplier 
Trasylol®/Aprotinin H2912 Bayer-miles, Germany 
Glass beads 267 02 50 Saarchem, South Africa 
Sodium hydroxide 582 31 80 Saarchem, South Africa 
Sodium carbonate 582 20 40 Saarchem, South Africa 
Folin & Ciocalteu’s reagent 243 300 Saarchem, South Africa 
Albumin T-3379 Sigma, USA St. Louis 
Thrombin 101141 ICN, USA 
Streptokinase 10114 ICN, USA 
CRP latex reagent 7003077 ABX Diagnostics, France 
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3.3 METHODS 
 
3.3.1 Specimen preparation 
Full blood count analysis was performed within four hours post 
venepuncture, after which the specimen was centrifuged, plasma 
separated and stored in 1.5 ml Eppendorf vials at –70°C for CRP 
analysis.  Clotted specimens were centrifuged; serum separated and 
stored in 1.5 ml Eppendorf vials at –70°C.  Platelet free plasma was 
obtained by centrifuging citrated blood twice, which was aliquoted and 
stored in 1.5 ml Eppendorf vials at –70°C. 
 
3.3.2 Fibrin network architecture variables 
These variables were performed on citrate plasma.  Thirty-five micro-litres 
of 10.000 KIU/ml Trasylol/aprotinin per nine volumes of citrate plasma 
was added, and thus used as an inhibitor of fibrin(ogen) lysis.  Plasma with 
trasylol was used for analysis of fibrin network content, compaction and 
mass-length ratio from turbidity.  Permeability was not performed because 
of the great degree of variation and the complexity of the method.  
Network lysis rate was performed on plasma without Trasylol®. 
 
3.3.2.1 Network fibrin content 
The method of Ratnoff & Menzies (1951) was used for duplicate 
determination of all network fibrin content.  For network fibrin content 
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0.9 ml plasma was pipetted into test tubes containing one gram glass 
beads and was clotted by addition of 100 µL Thrombin Reagent (1 IU/ml 
Thrombin final concentration, 25 mM Ca++ final concentration).  Samples 
were left overnight for maximum polymerisation.  All samples were 
centrifuged at 1300 X g and the supernatants were discarded.  The 
isolated networks were washed three times with saline solution.  One ml 
2.5 M NaOH was dispensed into each test tube and the networks were 
dissolved by heating the tubes for 15 minutes at 95°C.  The samples 
were left to cool at room temperature.  Seven millilitres water and three 
ml 1.9 M sodium carbonate were dispensed into each tube, containing 
200 µL of the NaOH-fibrin suspension.  The tubes were vortexed and 
mixed with one ml Folin-Ciocalteu's phenol reagent.  Samples were 
incubated at room temperature for 20 minutes and the absorbance 
measured at 650 nm.  Different concentrations of albumin were dissolved 
in 2.5 M NaOH and used to prepare a standard curve.  This standard 
curve was used to calculate the concentration of fibrin present in 
unknown samples. 
 
3.3.2.2 Mass-length ratio from turbidity (µT) 
The mass-length ratio from turbidity (µT) was determined in triplicate for 
each sample, using the method as described by Nair et al. (1991).  Nine 
hundred µL of platelet-poor plasma was pipetted into micro-cuvettes of 
one centimetre path length.  The plasma was mixed and clotted by 
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addition of 100 µL Thrombin Reagent (1 IU/ml Thrombin final 
concentration, 25 mM Ca++ final concentration).  Samples were left 
overnight for maximum polymerisation. 
 
The intercepts, A, in plots of c/T(λ)3 as a function of 1/(λ)2 were used to 
calculate µT according to the equation : 
µT = [10/1.48xA] x 1012 daltons/cm 
 
with c the network content, T the absorbance × 2.304 and λ the 
wavelength.  Turbidity (optical density) was measured at a range of 
wavelengths between 600 and 800 nm. 
 
3.3.2.3 Compaction of fibrin networks 
Compaction was measured in duplicate using the method as described 
by Dhall et al. (1976).  Nine hundred micro-litre of plasma was pipetted 
into 1.5 ml Eppendorf vials, pre-sprayed with lecithin-based aerosol 
(Spray-a-Cook) to render the surface non-adhering.  The plasma was 
clotted by introduction of 100 µL Thrombin Reagent (1 IU/ml Thrombin 
final concentration, 25 mM Ca++ final concentration).  Samples were left 
overnight for maximum polymerisation.  After centrifugation at 8000 X g 
for 45 seconds the volume of expelled sample from the fibrin networks 
was determined using a one ml syringe and expressed as a percentage 
of the initial volume.  
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3.3.2.4 Fibrin network lysis rate 
The network lysis rate was measured in duplicate using a method 
developed at the Fibrinogen Unit, Research laboratory.  Ninety µL of 
plasma was mixed and clotted by the introduction of 10 µL thrombin 
reagent (1 IU/ml thrombin final concentration, 25 mM calcium final 
concentration) in microtiter plates. After total polymerisation took place, 
50 µL of streptokinase with a final concentration of 100 U/ml was 
introduced to start lysis of networks.  The absorbance was measured 
with an ELISA plate reader at 608 nm for six hours at 10 minute intervals.  
The lysis rate was determined by plotting the time versus change in 
absorbance. 
 
3.3.3 Coagulation factor determinations 
All the coagulation measurements were performed on the Berhring 
coagulation timer automatic analyser, using methods listed in Table 3.4. 
 
TABLE 3.4 Methods used for coagulation factor determinations 
Measured variable Catalogue no Brand name Principle 
Factor VII OUHP 17 Thromborel® S Clot formation 
Factor VIII OQGS 17 Pathromtin® SL Clot formation 
Antithrombin III OWWR 17 Berichrom® AT III Chromogenic 
Fibrinogen OWZG 15 Multifibren® U Clauss' method 
Fibrin monomers OWXZ 11 Berichrom® FM Chromogenic 
D-Dimers$ OQWW 11 D-Dimer Plus Turbimetric 
$D-Dimer analyses were performed only on samples drawn on day 8 and 36.  These 
reagents where all provided by Dade Berhring, Marburg, Germany 
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3.3.4 Chemical analyses 
All the chemical analyses were performed on the Hitachi 902, automatic 
analyser, using methods listed in Table 3.5. 
 

	


Variables Cat. No. Principle Supplier 
Total cholesterol 1489323 Enzymatic colorimetric Roche Diagnostics 
LDL-Cholesterol 1985604 Enzymatic colorimetric Roche Diagnostics 
HDL-Cholesterol 1930672 Enzymatic colorimetric Roche Diagnostics 
Triglycerides 1488872 Enzymatic colorimetric Roche Diagnostics 
Free fatty acids FA115 Enzymatic colorimetric Randox Laboratories Ltd 
 
 
3.3.5 Full blood counts and C–Reactive protein measurements 
Full blood count was performed on the Coulter® MicroDiff 18, cell counter.  
The C-reactive protein (CRP) was determined on the MICROS CRP 
analyser, with a turbidimetric method where anti-CRP antibody was 
coupled with latex particles. 
 
3.4 STATISTICAL ANALYSES 
The statistical analyses were performed by the Department of Biostatistics, 
University of the Free State, Bloemfontein, using the SAS® programme.  
Data were summarised as means and standard deviation for each 
measured variable.  The differences between the means of the same 
variable but of a different time period were compared using the Student t-
test.  The difference between the different groups was compared using the 
ANOVA. 
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CHAPTER 4 
 
RESULTS 
 
4.1 INTRODUCTION 
 
Dietary fibre is said to help in the prevention of westernised diseases but 
the exact mechanism of action is not known.  In chapter two it has been 
explained that, dietary fibre is fermented in the large gut to short-chain 
fatty acids (acetate, propionate and butyrate).  It was also explained that, it 
is hypothesised that these SCFAs may, in part, contribute in some way to 
the beneficial effects of dietary fibre intake on human metabolism.  The 
aim of this study was to test the effects of different combinations of short-
chain fatty acids on some metabolic risk markers generally associated with 
the development of cardiovascular heart disease in westernised African 
men. 
A summary of the baseline results for the entire study group will be 
presented first, followed by the results of the different supplementation 
groups.  The results of the different groups were sub-divided into three 
categories, namely; (i) general health profile, which includes the 
anthropometrical, full blood count and CRP data; (ii) haemostatic profile, 
and (iii) lipid profile.  However, this study highlights the effects of the given 
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supplements on haemostatic risk factors and only a short description of 
the other risk variables will be given.   
 
 
4.2 BASELINE RESULTS OF THE ENTIRE STUDY GROUP 
 
Two baseline measurements were taken from each volunteer separated 
by a time-interval of seven days.  All subjects consumed placebo 
supplements for standardisation purposes between the two baseline visits.  
The results of the two baseline measurements will now be presented in 
order to provide information regarding the more general characteristics of 
the study population as a whole.  The reference ranges of the different 
variables are included as an aid to judging the results. 
 
4.2.1 General health profile of the entire study group for both baseline 
visits 
Anthropometrical measurements, blood cell counts and CRP 
concentrations of the two baseline visits for most of the study group were 
within the normal reference range, except for a few individual outliers.  
However, none of the outliers were clinically abnormal.  All subjects were 
therefore included in the study group. 
The results of baseline one was comparable to those of baseline two, with 
no statistically significant differences between the two visits. 
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4.2.2 Haemostatic profile of the entire study group for both baseline visits 
Haemostatic measurements of the two baseline visits for the group as a 
whole were within the normal reference range.  The results of baseline 
one was comparable to those of baseline two, with no statistically 
significant differences between the two visits. 
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A graphic presentation of the changes that occur during fibrin network 
lysis, as measured by means of turbidimetry, for both baseline visits of the 
group as a whole follow more or less the same pattern.  Similar rates of 
network lysis where measured up until 10 minutes, after which the curves 
both plateau at 180 minutes.  However, in comparison with baseline one, 
baseline two plateaus at a much higher absorbance. 
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4.2.3 Lipid profile of the entire study group for both baseline visits 
Mean lipid measurements of the two baseline visits for the entire group 
were within the normal reference range.  The outliers were not clinically 
abnormal, and therefore not excluded from the study.  The results of 
baseline one was comparable to those of baseline two, with no statistically 
significant differences between the two visits. 
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4.3 RESULTS OF THE INTERVENTION STUDY 
 
This section will be used to present the results measured in metabolic risk 
markers after supplementation with the three different short-chain fatty 
acid supplements.  Results for short-term changes (after 22 days of 
supplementation), end of supplementation changes (after 36 days of 
supplementation) and a wash out period of one week (after 43 days of 
supplementation) will be reported.  Focus will mainly be on the differences 
  61 
between day 8 (baseline 2; start of supplementation) and day 36 (end of 
supplementation). 
 
4.3.1 The Placebo Supplement Intervention Study Results 
The group consumed a placebo for the entire study period.  This group 
was composed of 25 volunteers but only 21 volunteers' results were used.  
The other four subjects’ results were excluded because some of the visits’ 
haemostatic specimens were clotted. 
 
4.3.1.1 Mean changes in the general health profile of the placebo supplement 
study group 
No significant changes were measured in any of the general health 
indicators from day 8 (start of supplementation phase) to day 36 (end of 
supplementation phase) within the placebo supplement group. 
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4.3.1.2 Mean changes in the haemostatic profile of the placebo supplement 
study group 
A statistically significant decrease (p = 0.047) in plasma fibrinogen 
concentration was measured from the start of supplementation (day 8) to 
the end of supplementation (day 36) within the placebo supplemented 
group.  No other significant changes in any of the other haemostatic 
variables were measured. 

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A graphic presentation of the turbidimetric changes that occur during 
fibrin network lysis, for all visits for the placebo supplemented group, 
followed more or less the same pattern.  Similar rates of lysis where 
initially measured up until 20 minutes, after which the graphs all reached 
a plateau at 190 minutes.  However, in comparison to all the other study 
periods, day 22 (after 2 weeks of experimental placebo supplementation) 
reached the plateau phase at a much lower absorbance. 
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4.3.1.3 Mean changes in the lipid profile of the placebo supplement study group 
No significant changes in any of the lipid variables were measured 
between day 8 (start of supplementation) and day 36 (end of 
supplementation) within the placebo supplemented study group. 
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4.3.2 The Acetate-Propionate (50/50) Supplement Intervention Study 
Results 
This study group consisted of 25 volunteers that consumed placebo 
supplement for a period of one week, followed by four weeks of 
experimental supplementation, which was composed of 50% acetate and 
50% propionate salts (sodium, potassium and calcium), after which one 
week of placebo supplementation followed. Only 23 volunteers' results 
were used in the final calculation because the others' haemostatic 
specimen were clotted and therefore excluded. 
 
4.3.2.1 Mean changes in the general health profile of the acetate-propionate 
supplement study group 
No significant changes were measured in any of the general health 
indicators between day 8 (start of supplementation) and day 36 (end of 
supplementation) for the acetate-propionate supplement group. 
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4.3.2.2 Mean changes in the haemostatic profile of the acetate-propionate 
supplement study group 
A statistically significant decrease in plasma factor VIII (p=0.016), 
antithrombin III (p<0.001), and an increase in plasma fibrinogen 
concentration (p=0.048) and the albumin/fibrinogen ratio (p=0.044), was 
measured between day 8 and day 36 within the acetate-propionate 
supplementation group.  No other changes in any of the other 
haemostatic variables were significant. 
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A turbidimetric presentation of the changes in the network lysis rate of all 
the study periods, for the acetate-propionate study group, showed a 
sharp rise in optical density for the first 40 minutes and reaching a 
plateau phase at approximately 190 minutes, except for day 22, where 
the maximum plateau phase was reached at 240 minutes.  In 
comparison with the other study periods day 1 reached a much lower 
maximum absorbance, while day 43 reached the highest maximum 
absorbance. 
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4.3.2.3 Mean changes in the lipid profile of the acetate-propionate supplement 
study group 
A statistically significant increase in both serum triglyceride (p<0.001) 
and percentage HDL-C (p=0.017) were found between day 8 and day 36 
within the acetate-propionate supplement group.  LDL-C (p<0.001) 
decreased significantly in that same period.  No other measured changes 
in any of the other lipid variables were significant. 
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4.3.3 The High-Acetate Supplement Intervention Study Results 
The baseline results of this group were comparable to the results of the 
other two groups.  The results presented are of 22 of the 25 volunteers, 
the other three's haemostatic specimen were clotted.  The volunteers also 
consumed placebo supplements for a period of at least one week, 
followed by four weeks of supplementation, which was composed of 70% 
acetate, 15% propionate and 15% butyrate, and ending with a week of 
placebo. 
 
4.3.3.1 Mean changes in the general health profile of the high-acetate 
supplement study group 
No significant changes were measured in any of the general health 
indicators between day 8 (start of supplementation) and day 36 (end of 
supplementation) for the high acetate supplement group. 
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4.3.3.2 Mean changes in the haemostatic profile of the high-acetate supplement 
study group 
A statistically significant decrease in plasma factor VII (p=0.018), factor 
VIII (p=0.011), antithrombin III (p<0.001) and fibrin monomers (p=0.002) 
was measured between day 8 and day 36 within the high acetate 
supplementation group, while compaction showed an increase (p=0.008).  
No other changes in any of the other haemostatic variables were 
significant. 
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
Figure 4.4 represents a graphic comparison between the changes in the 
fibrin network lysis rate during each study period, within the high-acetate 
supplement study group.  Turbidimetric changes showed a sharp 
increase in absorbance for the first 80 minutes and reached the plateau 
phase at 180 minutes, except for day 22 which reached it by 
240 minutes.  In comparison to the others, day 43 reached a much 
higher absorbance.  The rate of lysis of day 8 and day 36 did not differ 
significantly. 
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4.3.3.3 Mean changes in the lipid profile of the high-acetate supplement study 
group 
A statistically significant increase in serum total cholesterol (p=0.001) 
was measured from day 8 to day 36 within the high acetate supplement 
group.  No changes in any of the other lipid variables were significant. 
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CHAPTER 5 
 
DISCUSSION 
 
5.1 INTRODUCTION 
 
Coronary heart disease and stroke are considered as degenerative 
western diseases which in most cases can be prevented by a change in 
lifestyle, for example diet, physical activity and psychological well being.  
The link between haemostatic and lipid risk markers for coronary heart 
disease and stroke, and lifestyle (diet, exercise, stress, etc.) was 
explained in chapter two.  In this study a group of westernised African 
male volunteers were recruited and fed two different combinations of 
short-chain fatty acids, as well as a placebo supplement, for a period of six 
weeks.  Blood was drawn at different intervals and analysed to assess 
changes that were brought about by the different supplements.  Focus will 
be mainly on the differences between start of supplementation (day 8) and 
end of supplementation (day 36).  This chapter will be used to discuss the 
results which were presented in chapter four, therefore elucidating the 
effects that the different supplements had on haemostatic and lipid risk 
markers for coronary heart disease.  The discussion of the baseline results 
of the entire study group will be presented first, followed by the 
intervention study. 
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5.2 BASELINE CHARACTERISTICS OF THE ENTIRE STUDY GROUP 
 
Here a discussion of the baseline results is presented, so as to form a 
basis for understanding and interpreting the intervention study's results.  
The discussion of these baseline results will show if there were any 
abnormalities in this group of subjects, and will also evaluate the effect of 
placebo consumption for the run-in phase (which lasted a week), in so 
doing, its effectiveness in establishing a stable baseline. 
 
5.2.1 General health profile of the entire study group at baseline 
All subjects had blood pressures that were within the healthy range of the 
population group under investigation.  The way in which the blood samples 
and other measurements were collected may have contributed to the 
‘healthy’ results, mainly due to the fact that the subjects were all calm and 
treated with respect.  The nursing staff of the Defence Force was 
especially caring and friendly. No overweight or obese subjects were 
included for the purpose of this study, judging from the body-mass index, 
hip and waist measurements.  This could be ascribed to the inclusion 
criteria, and most importantly, the fact that the subjects were involved with 
physical activities most of the day, due to the nature of their occupation.  
The BMI and blood pressure measurements were similar to those 
obtained by epidemiological studies performed on Africans in South Africa; 
in Durban (Seedat, et al., 1992), Cape Peninsula (Oelofse, et al., 1996), 
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Free State (De Wet, 1999) and North West (James et al., 2000).  All these 
studies were investigating the effects of urbanisation on different risk 
factors for CHD and/or stroke. 
Blood counts for the purpose of this study were mainly evaluated as 
means of ‘marker’ for the general health.  It was not expected that the 
supplements should have any effect on these variables.  However, it was 
important to know that anaemic subjects or subjects with low platelets or 
white cell counts, which could be indicative of a wide variety of different 
disease states, were not included.  The blood cell counts reference ranges 
used in this study were established for African males in the Free State 
region (unpublished data – the experiments were done by the Department 
of Haematology and Cell Biology, University of the Free State, 
Bloemfontein, 1990), thus they are specific for the studied population.  
What can also be observed is that African people tend to have slightly 
lower red cell and white blood cell counts than the Caucasian population 
(Bain, 1995; Lewis, 2004).  C-reactive protein (an acute phase protein) 
was measured to ensure that possible changes in other haematological 
parameters may not be due to inflammation or any other unknown acute 
phase response, and also because it is associated with CHD and CVD.  
Luizzo and his colleagues (1994) found elevated plasma CRP 
concentration in the majority of patients with unstable angina, myocardial 
infarction, and a history of unstable angina.  While Ridker et al. (1997) 
suggested that the baseline plasma concentration of CRP in apparently 
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healthy men can predict the risk of first myocardial infarction and 
ischaemic stroke, independent of other risk factors. 
There were no statistically significant changes in any of the general health 
indicators for both baseline one (day 1) and baseline two (day 2) of the 
entire study group.  This indicates that the run-in phase with placebo 
managed to establish a stable baseline. 
 
5.2.2 Haemostatic profile of the entire study group at baseline 
Coagulation factor determination methods can be divided into two. In the 
first group, the factor activity is determined by clot formation time, which is 
proportional to the factor activity.  The second group measures the factor 
directly, especially by immunological methods, usually indicated as factor 
concentration, it does not matter whether the factor is functional or not.  
The units of measurements in general use are percentage for factor 
activity, while for concentration µg/l or mmol/l is used (Hutton et al., 1999).  
Thus it is important that when comparisons are made between studies that 
this difference is taken into account.  In this study, factor activity was used 
as the preferred method since it measures only the functional factor. 
Elevated FVII (Heinrich et al. 1994), FVIII (Pan et al. 1997) as well as 
plasma fibrinogen levels (Møller & Kristensen, 1991) are associated with 
increased risk of cardiovascular disease.  Cut off values for plasma 
fibrinogen for the African population group are a point of argument.  The 
main reason for this being the different views regarding the strength of 
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plasma fibrinogen as a predictor of stroke, compared to cardiovascular 
disease and the prevalence of these two diseases within the different 
population groups. The factor VII and VIII percentage activity were similar 
to those reported by De wet (1999).  The fibrinogen concentration of this 
study group was slightly lower than that reported by James et al. (2000).  
Antithrombin III (ATIII) is considered a natural anticoagulant; its deficiency 
is associated with thrombosis (Walker, 2004).  This might indicate that a 
higher than normal level will be to the advantage of the individual, but this 
needs thorough investigation and its association with coronary risk factor 
needs to be determined.  Both fibrin monomer and d-dimer levels are 
considered as potential risk markers for development of cardiovascular 
events.  The thrombin-catalysed released of the fibrinopeptides from 
fibrinogen results in the formation of a transient intermediate, termed fibrin 
monomer.  Increased fibrin monomers levels are found in patients with 
hypercoagulable disease state, especially after a cardiovascular event.  
The fibrin monomer results reported in this study where higher than those 
reported by De Wet (1999).  D-Dimer is a product of clotted fibrin 
breakdown, and is usually found in increased levels in patients with 
hypercoagulable disease states occurring before and after cardiovascular 
events.  It also indicates that fibrinolysis has occurred, thus it is increased 
in disseminated intravascular coagulation (Laffan & Manning, 2001). 
Fibrin network structure studies were performed because it is thought that 
the network structure contributes to the risk of developing coronary heart 
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disease (Mills et al., 2002).  The variables are mass-length ratio from 
turbidity (which measures fibre thickness), compaction (which measures 
the degree of cross-linking), and network lysis rate.  The fibrin network 
content reported in this study was similar to those reported by Pieters et 
al. (2002) and Veldman et al. (1999), while the mass-length ratio was 
lower and the compaction higher in this study report. This discrepancy 
might be due to the different population groups that were used in these 
studies.  Indicating that Africans might have these lower mass-length ratio 
and higher compaction, but this needs population studies to evaluate this 
supposition.  Gabriel et al. (1992) has suggested that fibrin structure 
contributes to the regulation of the fibrinolytic rate; this is one of the 
reasons why fibrin network lysis rate studies were performed.  The fibrin 
network lysis rates of the two baseline visits were similar, while the end-
point absorbance of baseline one was lower.  The reason for this 
observation was that baseline two’s (day 8) plasma fibrinogen 
concentration and the network fibrin content was higher than that of 
baseline one (day 1).  The fibrin network content is a measure of the 
amount of fibrin that is incorporated into the network structure, and it being 
high indicated that there was more fibrinogen was incorporated into the 
network structure.  Therefore, more fibrinogen was available and indeed 
was incorporated into the network structure, thus resulting in a higher end 
point absorbance. 
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There were no statistically significant changes in any of the haemostatic 
variables for both baseline one (day 1) and baseline two (day 8) of the 
entire study group.  This indicates that the run-in phase with placebo 
managed to establish a stable baseline. 
 
5.2.3 Lipid profile of the entire study group at baseline 
The lipid profile of this group of subjects is very interesting.  The total 
cholesterol (TC) level of this group falls within the moderate risk category 
(4.10 – 5.50 mmol / L).  The fasting TG levels fall below the high risk cut-
off level of 2 mmol /L (Wilson et al., 1991).  The HDL-C levels are 
relatively high when compared to the total cholesterol levels.  However, in 
comparison with the HDL-C, concomitant high LDL-C levels (up to 54% of 
the TC) were measured.  In general, this is very common within this 
population group.  Consequently, at first glance, the lipid profiles seem 
healthy.  However, the LDL-C levels (taking into consideration that it is 
lifestyle associated, as well as the group of the volunteers) place the 
subjects at risk of future cardiovascular events.  The TC, TG, %HDL-C, 
HDL-C & LDL-C are comparable to those found by James, et al. (2000), 
Oelofse, et al. (1996) and Seedat, et al. (1992).  The fasting Non-Esterified 
Fatty Acid level of this group falls within the accepted normal range.  
Normal daily values can fluctuate to as much as 10 mmol / L, depending 
on the fat content of the diet of an individual. 
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There were no statistically significant changes in any of the lipid variables 
for both baseline one (day 1) and baseline two (day 8) of the entire study 
group.  This indicates that the run-in phase with placebo managed to 
establish a stable baseline. 
 
 
5.3 INTERVENTION STUDY RESULTS 
 
Here a discussion of results of different study groups is presented.  Focus 
was on the results of day 8 (start of supplementation) and day 36 (end of 
supplementation).  The baseline measurements of the different groups 
were comparable with no statistically significant differences thus any 
changes which were observed in any of the groups cannot be said that 
they were caused by different baseline results.  From this observation it 
can be assumed that the changes were brought about by the different 
supplements. 
 
5.3.1 The Placebo Supplement Intervention Study group 
This study group consumed placebo supplements for the entire study 
period. 
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5.3.1.1 Changes in the general health profile of the placebo supplement study 
group 
No statistically significant changes in any of the general health indicators 
within the placebo group were measured during the study, more 
importantly between day 8 (start of supplementation) and day 36 (end of 
supplementation).  This can be seen as a positive result since the group 
consumed placebo and no significant changes were expected.  It is 
interesting to note that the plasma CRP concentration of day 8 was 
higher than any of the other visits, though it was not statistically 
significant.  This could be due to an unknown inflammatory response or 
infection. 
 
5.3.1.2 Changes in the haemostatic profile of the placebo supplement study 
group 
A statistically significant change was observed in the plasma fibrinogen 
concentration, which showed a decrease for the period from day 8 to day 
36, and no statistically significant change was measured in any of the 
other haemostatic variables.  When looking at all the visits it can be 
noticed that the fibrinogen concentration of day 8 was the highest for all 
of the visits, and this was also the case with factor VIII concentration 
though the change was not statistically significant.  Since factor VIII, CRP 
and fibrinogen concentration are all acute phase proteins, it follows logic 
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that the statistically significant change in fibrinogen might not have been 
brought about by the supplements, but an inflammatory response. 
Fibrin network lysis rate of day 1, 8, 36 and 43 showed the same pattern 
and similar lysis rates, while day 22 reached a lower end-point 
absorbance, which cannot be explained by the fibrinogen concentration.  
It can be noticed that the network fibrin content of day 22 was lower than 
that of all the other visits, and this could explain why day 22 end-point 
absorbance was lower than that of the other visits.  Most importantly, 
there was no significant change from day 8 and day 36. 
 
5.3.1.3 Changes in the lipid profile of the placebo supplement study group 
No statistically significant changes were measured within the lipid 
variables of the placebo group, because this study group consumed 
placebo which was not supposed to affect the lipid variables. 
 
5.3.2 The Acetate-Propionate (50/50) Supplement Intervention Study 
Results 
This group consumed placebo from day 1 to day 8, followed by the 
acetate-propionate supplements until day 36, and then consumed placebo 
for the last week. 
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5.3.2.1 Changes in the general heath profile of the acetate-propionate (50/50) 
supplement study group 
No significant changes were observed in any of the general health 
indicators of the acetate/propionate (half-half) supplemented group over 
the duration of the study.  This can be viewed as positive because no 
changes were expected in these variables since these variables were 
only used to assess general health status of the volunteers. 
 
5.3.2.2  Changes in the haemostatic profile of the acetate-propionate (50/50) 
supplement study group 
A statistically significant decrease in factor VIII activity, antithrombin III 
and an increase in fibrinogen concentration were measured within this 
group from baseline to end of supplementation (day 8 and day 36).  No 
statistically significant changes in any of the haemostatic variables were 
measured.  The change in factor VIII could be viewed as positive 
because some studies have suggested that an increase in factor VIII is 
associated with increased risk of coronary heart disease development.  
The changes in ATIII and fibrinogen could render the blood more 
coagulable and the individual at higher risk of development of 
cardiovascular complications.  This is only supported if the assumption 
that a decreased ATIII makes the blood more coagulable.  An increase in 
fibrinogen was not accompanied by the high CRP and factor VIII, as was 
the case with the placebo group, thus indicating that the change is not an 
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acute phase response.  There were no statistically significant changes in 
the fibrin network architecture, as was seen with Veldman et al. (1999) 
but the discrepancy is caused by the amount of acetate fed and the fact 
that in this study propionate was also included in the supplements.  
These changes are not clinically significant. 
Network lysis rate of day 8, 22, and 36 showed similar rate of lysis, while 
day 43 reached the highest end-point absorbance, contrary to day 1 
which reached the lowest.  The network fibrin content of day 1 was the 
lowest of all the visits, while day 43 had a couple of samples with high 
network fibrin content, this is reflected by the high standard deviation. In 
contrast to day 8's fibrin network content that had a low standard 
deviation, indicating that the range for this visit was small.  Most 
importantly day 8 and day 36 showed no significant change. 
 
5.3.2.3 Changes in the lipids profile of the acetate-propionate (50/50) 
supplement study group 
Triglyceride levels showed a statistically significant increase from start to 
the end of supplementation.  An increase in TG could be viewed as 
making the individual susceptible to cardiovascular events, but in this 
case the increase is still well below the high risk cut-off level of 2 mmol/L.  
Also, a significant decrease in LDL-C was measured from baseline two 
(day 8) to the end of the supplementation phase (day 36).  In comparison 
with TC levels (LDL-C/TC X 100), the LDL-C fraction dropped from 64% 
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(day 8) to 57% (day 36).  This in itself may have some clinical 
significance.  The rise in HDL-C was small and statistically non-
significant, but with the decrease in LDL-C caused the %HDL-C to rise 
from 26% to 30%.  The statistically significant decrease in LDL-C and a 
concomitant rise in %HDL-C (HDL-C/TC X 100) can be considered as 
positive changes, thus reducing the risk of cardiovascular events.  These 
changes can be related to those found by Veldman et al. (1999) where 
acetate and pectin were given as supplements, and Venter et al. (1997) 
where feeding a western diet together with 2% propionate showed an 
increase in HDL-C. 
 
5.3.3 The High-Acetate Supplement Intervention Study Results 
This group consumed placebo from day 1 to day 8, followed by high-
acetate supplements till day 36, and then consumed placebo for the last 
week. 
 
5.3.3.1 Changes in the general health profile of the high-acetate supplement 
study group 
No significant differences in any of the general health indicators of the 
high acetate supplemented study group were measured, from the start to 
the end of supplementation, as indicated no changes were expected. 
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5.3.3.2 Changes in the haemostatic profile of the high-acetate supplement study 
group 
The changes that affect the cardiovascular disease risk profile positively 
are, a decrease in factor VII, factor VIII, and fibrin monomers, while a 
decrease in AT III is unknown, compaction’s increase affects the risk 
profile negatively.  The more compact network would have a high degree 
of cross-linking, thus will not allow easy access for fibrinolytic enzymes 
(Nair & Shats, 1997; Blombäck et al., 1992).  The significant results 
within haemostatic variables of this subject group are difficult to interpret, 
mainly due to the fact that some changes could be considered as 
beneficial (the decrease in FM levels), and the others as less beneficial 
(an increase in compaction).  It will be necessary to weigh these changes 
against each other, without speculating too much.  Though changes were 
not found in the fibrin network structure as in Veldman et al. (1999), but 
this group showed more changes in the haemostatic variables than the 
acetate-propionate supplement group.  It must be remembered that the 
supplement of this study does not produce the same SCFAs ratio as 
pectin.  No other significant changes were measured within this subject 
group. 
Network lysis rate of all the visits showed a similar rate of lysis with no 
statistically significant changes amongst them.  Day 43 showed a high 
end-point absorbance because it had the highest fibrin network content 
and had a few samples with high fibrin network content values as 
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reflected by the standard deviation and raw data.  Day 22's lysis rate 
seemed to increase periodically and it reached plateau after all the other 
visits and it had the second highest end-point absorbance which makes 
sense because this visit had the second highest fibrinogen concentration.  
The change in compaction was small and therefore was not reflected in 
the network lysis rate. 
 
5.3.3.3 Changes in the lipids profile of the high-acetate supplement study group 
Total cholesterol within this supplemented group showed a statistically 
significant increase of approximately 4.2%, compared to no difference 
within the placebo group.  This increase was caused by a small statistical 
non-significant increase in LDL-C (8%) and HDL-C (5.2%), while the 
%HDL-C remained constant.  At first glance the change looks negative 
but when examined closer the change is not so cut and dry.  These 
results are a bit tricky to evaluate since a positive and a negative change 
has taken place.  When looking at the %HDL-C and %LDL-C (both 
relative to TC) there is not much change in these variables.  A decrease 
of approximately 4.2% should have a clinical impact, especially if other 
variables followed this route.  The difference, however, is very small 
when compared to clinical significance. It is interesting to note the 
statistical non-significant decrease in NEFA levels (of 25%).  This change 
is expected and ascribed to increase short-chain fatty acid circulation.  It 
is this decrease in the NEFA concentration that was believed to lower 
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circulation plasma fibrinogen concentrations (Veldman et al., 1999).  
However, this hypothesis could never be proven. No other significant 
changes of interest in any of the lipid variables within this group were 
observed. 
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CHAPTER 6 
 
CONCLUSION AND RECOMENDATIONS 
 
6.1 INTRODUCTION 
 
Coronary heart disease and stroke are considered as degenerative 
western diseases which in most cases can be prevented by a change in 
lifestyle, for example diet, physical activity and psychological well being. 
Africans have the lowest incidence of these westernized disorders, in 
comparison to other South African population groups.  This is thought to 
be due to the prudent, low-fat high fibre diet which Africans consume. The 
protection seems to centre on and around the intake of dietary fibre, but 
the exact mechanism of action is not known. Dietary fibre is fermented in 
the large gut to short-chain fatty acids (acetate, propionate and butyrate). 
It is hypothesized that these SCFAs may, in part, contribute in some way 
to the beneficial effects of dietary fibre intake on human metabolism. 
The aim of this study was to test the effects of different combinations of 
short-chain fatty acids on some metabolic risk markers generally 
associated with the development of cardiovascular heart disease in 
westernised African men. In this study a group of westernised African 
male volunteers were recruited and fed two different combinations of 
short-chain fatty acids, as well as a placebo supplement, for a period of six 
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weeks.  Blood was drawn at different intervals and analysed to assess 
changes that were brought about by the different supplements.  Focus 
was mainly on the differences between start of supplementation (day 8) 
and end of supplementation (day 36). 
The conclusion of the baseline characteristics of the entire study group will 
be presented first, followed by the intervention study, where the conclusion 
of the different study groups will be presented, ending with the 
recommendations. 
 
 
6.2 BASELINE CHARACTERISTICS OF THE ENTIRE STUDY GROUP 
 
The characteristics of this group of subjects reflect a group of people 
without current metabolic abnormalities, as reflected by the baseline 
results and discussions. This could be ascribed to the strict inclusion 
criteria adhered to during the recruitment phase.  The anthropometrical 
measurements reflect that this group of subjects were not clinically obese, 
while the blood pressure and blood counts were also within range for this 
population. 
The haemostatic measurements were within the reference ranges for this 
subject group.  The lipid profile of this group reflected a normolipidaemic 
group with a slight change to the westernised lipid profile though not 
pronounced. 
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There was no significant changes, statistical or clinical, observed between 
the two baselines. This indicated the placebo supplement was successful 
in establishing a stable base line. 
 
 
6.3  INTERVENTION STUDY 
 
The baseline results of the three study groups were not statistically and 
clinically different, indicating that any other significant changes cannot be 
attributed to bias, because of a different baseline. 
 
6.3.1 The Placebo Supplement Intervention Study Results 
The supplements did not affect the anthropometrical measurements, blood 
pressure, blood cell counts and CRP as none of them showed a 
statistically and clinically significant change from the beginning of the 
intervention period to the end of the study. 
The placebo supplement did not affect the haemostatic variables including 
fibrin network architecture variables. The statistically significant increase in 
fibrinogen might have been brought about by an inflammatory reaction 
because CRP and factor VIII were also high for that period, though not 
statistically significant. The CRP and Factor VIII changes were also not 
clinically significant. 
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The lipid variables of the placebo group were not affected by these 
supplements. This is viewed as being positive since no significant changes 
were expected in any of the measured variables of this group of subjects. 
 
6.3.2 The Acetate-Propionate (50/50) Supplement Intervention Study 
Results 
The general health indicators were not affected by the supplements; this 
was expected since these were only used as a measure of general health. 
A statistically significant decrease in factor VIII can be viewed as a positive 
change, while an increase in fibrinogen is viewed as negative changes. 
Though statistically significant these two variables are not clinically 
significant. The decrease in ATIII has to be evaluated further, so as to 
determine if a decrease or an increase can be associated with increased 
risk of CHD. 
A statistically significant decrease in LDL-C from 64% to 57%, combined 
with a statistically non-significant increase in HDL-C from 26% to 30% can 
be considered positive effects. While a decrease in triglycerides is 
negative, but it was well below the cut-off point 
This supplement tended to have affected more lipid variables than the high 
acetate group. The acetate–propionate supplement did not have an effect 
on the fibrin network structure variables, but had an effect on other 
haemostatic variables together with lipid variables. 
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6.3.3 The High-Acetate Supplement Intervention Study Results 
The general health indicators were not affected by the supplements; this 
was expected since these were only used as a measure of general health. 
A statistically significant decrease in factor VII, VIII and fibrin monomers 
are considered to lower the risk of cardiovascular events. While a increase 
in compaction tend to increase the risk of cardiovascular events. The 
contribution of ATIII to CHD risk has still to be determined. 
There was a statistically significant increase in total cholesterol of 4.2%, 
this was caused by an increase in LDL-C and HDL-C of 8% and 5.6% 
respectively. 
This study group showed more changes in the haemostatic variables than 
the acetate-propionate supplemented group. The high acetate 
supplements showed only one significant change in the fibrin network 
structure studies (which was negative), but had an effect on other 
haemostatic variables and only a single change in lipid variables. 
 
6.3.4 The overall general conclusion 
The placebo supplement did not affect the haemostatic variables including 
fibrin network architecture variables. The acetate-propionate (50/50) 
supplement affected more lipid variables than the high acetate group. 
While the high acetate study group showed more changes in the 
haemostatic variables than the acetate-propionate supplemented group. 
 
  100 
6.4 RECOMMENDATIONS 
 
6.4.1 Future research 
Is it not time to look closer at fibrin network structure studies for answers 
for hypercoagulation patients, where a cause for the increased risk for 
thrombosis is not determined by the tests that are currently done? The 
researcher suggests a multi-centre study to investigate the effect of fibrin 
network structure on the risk for hypercoagulation, thus determining if 
fibrin network structure studies are an independent risk marker or not. This 
study will also help to determine the cut-off point for risk and on the other 
assist with the standardisation of the different methods used for fibrin 
network structure studies. 
Another study would be to determine the effect of SCFA and fibre on 
people who are at risk and even have had an event so as to assess the 
effect under these “abnormal” conditions. 
 
6.4.2 Dietary recommendations and possible clinical use 
On the basis of the results obtained and results from other similar studies 
it has become very important to make the general public aware of the 
importance of fibre in the diet, notwithstanding the importance of a 
balanced diet. For those individuals who may have allergies or are 
intolerant to certain types of fibre may look towards SCFA supplements as 
a substitute, though it does not give all the benefits of fibre. 
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APPENDIX: A 
CONSENT FORM 
 
 
THE EFFECTS OF SHORT-CHAIN FATTY ACIDS ON HAEMOSTATIC RISK FACTORS FOR 
CARDIOVASCULAR HEART DISEASES IN WESTERNISED BLACK MEN 
 
 
DECLARATION BY OR ON BEHALF OF THE PARTICIPANT 
 
I, undersigned, 
……………………………………………………………………………………………………………... of 
…………………………………………………………………………………………………………………
………….. 
…………………………………………………………………………………………………………………
… (Address) 
Identity number: …………………………………………… 
 
A I confirm that: 
 
1. I have been asked to participate in the above-mentioned research project, carried out by the 
Fibrinogen Unit, Technikon Free State and University of the Orange Free State. 
 
2. The information including the purpose of the study, advantages and disadvantages have been 
completely explained to me. 
 
3. I give my permission for the use of the results obtained in this research project for publication 
purpose, thus making other scientists aware of the findings as long as my anonymity is protected 
at all times. The information obtained will be confidential. 
 
4. It was clearly explained to me that I can refuse to participate in this study or I can withdraw my 
permission to participate at any time. If I refuse or withdraw, I will not be disadvantaged in any 
way and it will not be held against me. 
 
5. The information was explained to me by 
…………………………………………………………….. (name of interviewer) in 
…………………... (language) and I confirm that I have good command of this language and 
understood the explanations. I was also given the opportunity to ask questions on things I did not 
understand, and I can also ask further questions at any time during the project. 
 
6. No pressure was applied on me to take part in this research project. 
 
B I hereby agree voluntarily to take part in this research project. 
 
Signed/confirmed at ………………………………………….... on ………………………...2000 
 
 
…………………………………….. (signature) ……………………………………… 
Participant           Witness 
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DECLARATION BY OR ON BEHALF OF RESEARCHER 
 
 
I, ………………………………………………………………………………………..…………., declare 
that: 
 
1. I have explained the information in this document and about the project to 
…………………………….. 
……………………………..……….. (name of participant). 
 
2 I asked the participant to ask any questions if something was not clear. 
 
3 That the interview was conducted in English, Afrikaans, or ………………….. (language) OR that 
the interview was conducted in ……………………. (language) with the help of a translator, 
…………………………………………(name of translator). 
 
 
 
 
Signed/confirmed at ………………………………………….... on ………………………...2000 
 
 
 
 
…………………………………….. (signature) ……………………………………… 
Researcher or his representative          Witness 
 
 
 
 
DECLARATION BY TRANSLATOR 
 
 
I, ………………………………………………………………………………………..…………., declare 
that: 
 
1 I have translated the content of this document from English/Afrikaans into ………………….. 
(language) to …………………………………………..…. (name of participant) and that I have 
translated the participant’s questions to the researcher or his/her representative as well as the 
answers of the latter to the participant. 
 
2 That the information that I have so translated was a correct interpretation of what I was asked to 
translate 
 
Signed/confirmed at ………………………………………….... on ………………………...2000 
 
 
 
…………………………………….. (signature) ……………………………………… 
Translator            Witness 
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FOROMO YA TUMELLO 
 
 
FATTY ACIDS TSA KETANE TSE KHOTSWANE DI TSHWENYA JWANG MATSHWAO A 
LEFU LA PELO MO BANNENG BA BATHO BANTSHO 
 
 
 
BOIKANO KA, KAPA MO SEBAKENG SA MO NKA 
KAROLO 
 
 
Nna, …………………………………………………………………………………………………… mo 
nka karolo, wa 
…………………………………………………………………………………………………………………
………… 
…………………………………………………………………………………………………………………
…. (aterese) 
Nomoro ya boitsibiso: …………………………………… 
 
 
A Ke dumela hore: 
 
1. Ke kopilwe hore ke nke karolo resetjheng eo ho buiwang ka yona hodimo, e etswa ke Fibrinogen 
Unit, Technikon ya Foreisetata le University ya Foreisetata. 
 
2. Ke hlaloseditswe maikemisetso, melemo le dikotsi tsa resetjhe ena ka botlalo. 
 
3. Ke fana ka tumello ya ka hore diphetho tsa resetjhe ena di sebedisetswe ho ngola atikele etla 
tsibisa bo rra saense ba bang ka diphitlhelelo tsena, empa dipheto di tla ba sephiri, feela di tla 
sebediswa fa lebitso la ka le sa hlahe ka nako tsohle. 
 
4. Ke hlaloseditswe hore nka hanna ho nka karolo, kapa nka hula tumello ya ka ya ho nka karolo ka 
nako e ngwee le e ngwee, mme sena ha se na ho sebediswa kgahlano le nna. 
 
5. Ke hlaloseditswe ka resetjhe ke 
…………………………………………………………………………….. (lebitso la mohlalosi) ka 
………………………(puo) ke a dumella hore puo ena ke a e utlwisisa le hona ho e tseba. Ke 
fuwe sebaka sa ho botsa dipotso ka dintho tseo ke neng ke sa di utlwisise, ke utlwisisa hore nka 
botsa ka nnako e ngwee le e ngwee ha resetjhe e tsweletse. 
 
6. Ha ke a bewa ka tlasa khatelelo hore ke nke karolo mo resetjheng ena. 
 
B. Ke dumella ka ho rata ha ka ho nka karolo mo resetjheng ena. 
 
 
E saennwe ……………………………………………. . (sebaka), ka la …………………………….. 2000 
 
 
 
………………………………………….   …………………………………………. 
Mo nka karolo        Paki 
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BOIKANO KA KAPA MO SEBAKENG SA MORESETJHI 
 
 
Nna, ……………………………………………………………………………………………, ke ikana 
hore: 
 
1. Ke hlaloseditse ……………………………………………………………………… (lebitso la mo 
nka karolo) ka resetjhe le foromo ena. 
 
2. Ke bolleletse mo nka karolo ho botsa dipotso ha e ba a sa utlwisise 
 
3. Dipotso le thlahiso lesedi di ne di nne di le ka English, Afrikaans, kapa 
………………………(puo); kapa dipotso di ne di botswa ka ……………………..(puo) ka thuso 
ya mofetoledi, ……………………… 
……………………….(lebitso la mofetoledi). 
 
 
E saennwe ……………………………………………. . (sebaka), ka la …………………………….. 2000 
 
 
 
 
 
………………………………………….   …………………………………………. 
Moresetjhi       Paki 
 
 
 
 
BOIKANO KA MOFETOLEDI 
 
 
Nna, ……………………………………………………………………………………………, ke ikana 
hore: 
 
1. Ke fetoletse ntshetso lesedi le dipotso ho tswa ho English/Afrikaans ho ya ho 
…………………………... (puo) ho ………………………………………………………..(lebitso 
la mo nka karolo), le dikarabo ho tswa ho moresetjhi ho ya ho mo nka karolo. 
 
2. Ke fetoletse di ntho tseo ho neng ho thwe ke di fetolele hantlhe 
 
 
E saennwe ……………………………………………. . (sebaka), ka la …………………………….. 2000 
 
 
 
 
………………………………………….   …………………………………………. 
Mofetoledi         Paki 
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APPENDIX: B 
 
TECHNIKON FREE STATE FIBRINOGEN UNIT 
 
SCFA PROJECT: RECRUITMENT QUESTIONNAIRE 
 
 
DATE:   ______/__________/_________ 
 
INTERVIEWER:  ___________________ 
 
SURNAME AND INITIALS: 
__________________________________________________ 
 
HOUSE DOCTOR: 
_________________________________________________________ 
 
PATIENT: 
NAME:_________________________________________ 
 
  
ADDRESS:______________________________________ 
 
                  ______________________________________ 
 
                  ______________________________________ 
 
 
SECTION/DEPARTMENT:____________________ 
 
 
TEL:                             ____________________________ 
 
 
AGE:                        ______years______months 
 
 
SMOKING HABITS: 
 
 YES 
 
 NO 
 
 
BODY MASS:          ____________cm 
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LENGTH:                 ____________kg 
 
 
BLOOD PRESSURE: _____/_____ 
 
 
ACTIVITY LEVEL: 
 
 INACTIVE 
 
 MEDIUM ACTIVE 
 
 ACTIVE 
 
FAMILY HISTORY: 
 
 CORONARY HEART DISEASE _____ 
 DIABETES MELLITUS  _____ 
 HYPERCHOLESTEROLAEMIA _____ 
 OTHER (specify): 
 
 _____________________________________ 
 
 
MEDICAL HISTORY: 
 
 ANGINA/CORONARY HEART DIASEASE     _____ 
 MYOCARDIAL INFARCTION _____ 
 STROKE _____ 
 BYPASS _____ 
 BLOOD CLOTS _____ 
 HIGH BLOOD PRESSURE _____ 
 DIABETES TYPE I/II _____ 
 FAMILIAL CHOLESTEROL _____ 
 
 
ANY CHRONIC DISEASES MEDICATION: 
 
 YES 
 
 NO 
 
SPECIFY:_______________________________________ 
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HOW OFTEN DO YOU USE ALCOHOL: 
 
DAILY 
 
WEEKLY 
 
MONTHLY 
 
OTHER: __________________________ 
 
 
BLOOD TESTS 
 
BLOOD CHOLESTEROL: _________ 
 
FASTING GLUCOSE: _________ 
 
PLASMA FIBRINOGEN: _________ 
 
 
FOR OFFICE USE ONLY: 
 
SUBJECT:                APPROVED                         REJECTED 
 
 
ASSIGNED SUBJECT NO:  
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 APPENDIX:C 
 
QUESTIONNAIRE FOR SUBJECTS WHO COMPLETED THE STUDY 
 
Please answer the following questions regarding your participation in the research study: 
 
 
Respondent number:     _______________________ 
 
 
Employee Number:   _______________________ 
 
1.  Did you experience any vomiting during the study? 
 
 1. Yes 2. No 
 
If yes, how many times? 
 
 1. After each meal 2. Once a day 3.  Once a week 
 
  4.  Other 
 
2.  Did you experience any flatulence during the study? 
 
 1. Yes 2. No 
 
If yes, how many times? 
 
 1. After each meal 2. Once a day 3.  Once a week 
 
  4.  Other 
 
3.  Did you experience any stomach cramps during the study? 
 
 1. Yes 2. No 
 
If yes, how many times? 
 
 1. After each meal 2. Once a day 3.  Once a week 
 
  4.  Other 
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4.  Did you experience any changes in your lifestyle during the study? 
 
 1. Yes 2. No 
 
If yes, describe the changes: 
 
 
 
 
 
 
 
 
 
5.  Did you experience any constipation during the study? 
 
 1. Yes 2. No 
 
If yes, how frequent? 
 
 1. After each meal 2. Once a day 3.  Once a week 
 
  4.  Other 
 
 
 
6.  Did you experience an increased appetite during the study? 
 
 1. Yes 2. No 
 
If yes, explain: 
 
 
 
 
 
 
 
7.  Did you experience any changes in your alcohol consumption during the study? 
 
 1. Yes 2. No 
 
 
If yes, to what extent? 
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8.  Did you use any medication/supplements during the study? 
 
 1. Yes 2. No 
 
If yes, what is the name of the medication/supplement you used? 
 
 
 
 
 
 
If yes, how many times did you use this medication/supplement? 
 
 1. After each meal 2. Once a day 3.  Once a week 
 
  4.  Other 
 
 
and for how long (days)? 
 
 
9.  Did you consume all of the experimental capsules every day? 
 
 1. Yes 2. No 
 
10.  Was the amount of capsules consumed acceptable? 
 
 1. Yes 2. No 
 
11.  Would you be willing to consume these capsules daily if they are considered as 
healthy? 
 
 1. Yes 2. No 
 
12.  Did you experience any other side-effects of the supplement during the study? 
 
 1. Yes 2. No 
 
If yes, please specify? 
 
 
If yes, how frequent? 
 
 1. After each meal 2. Once a day 3.  Once a week 
 
 4.  Other 
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13.  Did you experience any positive effects on your health during the study? 
 
 1. Yes 2. No 
 
If yes, explain. 
 
 
 
 
 
 
 
14.  Do you have any other comments you would like to make regarding the study? 
 
 
 
 
 
 
 
The research team would like to thank you for your co-operation during the study.  The 
project is very important for gaining new scientific knowledge.   
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APPENDIX D 
